Charlotte F. and Irving W. Rabb Professor of Medicine
Babusis D, Curry MP, Kirby B, Park Y, Murakami E, Wang T, Mathias A, Afdhal N, McHutchison JG, Ray AS
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. Antimicrob Agents Chemother. 2018 05; 62(5).
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis. 2018 Feb; 5(2):ofy001.
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.
Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, Xu L, Eng F, Afdhal N, Kalluri R
Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology. 2003 Jan; 124(1):147-59.
Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors.
Keane TE, Dillon B, Afdhal NH, McCormack CJ
Conservative management of perforated duodenal ulcer. Br J Surg. 1988 Jun; 75(6):583-4.
Conservative management of perforated duodenal ulcer.
Loomba R, Gindin Y, Jiang Z, Lawitz E, Caldwell S, Djedjos CS, Xu R, Chung C, Myers RP, Subramanian GM, Goodman Z, Charlton M, Afdhal NH, Diehl AM
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2).
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.
El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, McHutchison J, Brainard DM, Terrault N, Curry MP
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
Infectious disease clinics of North America
Antiviral therapy for treatment naïve patients with hepatitis C virus. Infect Dis Clin North Am. 2006 Mar; 20(1):99-113, vi-vii.
Antiviral therapy for treatment naïve patients with hepatitis C virus.
Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Andres Cardenas, BIDMC, Boston, MA; Monica Guevara Univ Barcelona, Barcelona, Spain; Peter Gross Unvi Car; Gustav Carus Dresden, Dresden, Germany; Joseph varbalis, Georgetown Univ Medical center, Washington, DC; Thomas Berl; Robert Schrier, Univ of Colorado health Science Center, Denver, CO; Daniel Bichet Hospital de sacre Courer de Montreal, Montreal Canada; Lynn Wagoner, Univ of Cinncinnati Heart and Vascular Center. Cincinnati, OH; John Ouyang; Cesare Orlandi; Frank Czerwiec, Otsuka Maryland Research Institute, Rockville, MD
Randomized Placebo-Controlled trial of Tolvaptan, a novel v2-receptor antagonist, in hyponatremia: results of the salt 2 trial with emphasis on efficacy and safety in cirrohosis. hepatology. 2005; 42(4):172A.
Randomized Placebo-Controlled trial of Tolvaptan, a novel v2-receptor antagonist, in hyponatremia: results of the salt 2 trial with emphasis on efficacy and safety in cirrohosis
V.M. Byrnes, H. Shi, S. Kiryu, N.M. Rofsky, N.H. Afdhal. Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Deparment of Radiology, Beth Israel Deaconess medical Center, Boston, MA, USA
The Fate of Arterial Enhancing Nodules on MRI in the Cirrhotic Liver. Journal of Hepatology. 2005; 42(4):90-91.
The Fate of Arterial Enhancing Nodules on MRI in the Cirrhotic Liver
Hepatitis C treatment of patients in an urban medical center. Hepatology. 2000; (32):565A.
Hepatitis C treatment of patients in an urban medical center
Afdhal NH, Niu N, Nunes DP, Bansil R, Cao XX, Gantz D, Small DM, Offner GD
Mucin-vesicle interactions in model bile: evidence for vesicle aggregation and fusion before cholesterol crystal formation. Hepatology. 1995 Sep; 22(3):856-65.
Mucin-vesicle interactions in model bile: evidence for vesicle aggregation and fusion before cholesterol crystal formation.
Zijlstra AI, Offner GD, Afdhal NH, van Overveld M, Tytgat GN, Groen AK
The pronase resistance of cholesterol-nucleating glycoproteins in human bile. Gastroenterology. 1996 Jun; 110(6):1926-35.
The pronase resistance of cholesterol-nucleating glycoproteins in human bile.
What prevents the gallbladder from digesting itself? Studies of taurochenodeoxycholate toxicity. Gastroenterology. 1996; (110):1268A.
What prevents the gallbladder from digesting itself? Studies of taurochenodeoxycholate toxicity
Kline TJ, De las Morenas T, O'Brien M, Smith BF, Afdhal NH
Squamous metaplasia of extrahepatic biliary system in an AIDS patient with cryptosporidia and cholangitis. Dig Dis Sci. 1993 May; 38(5):960-2.
Squamous metaplasia of extrahepatic biliary system in an AIDS patient with cryptosporidia and cholangitis.
Liver international : official journal of the International Association for the Study of the Liver
Liver masses and eosinophilia. Liver Int. 2008 Jan; 28(1):150.
Flamm SL, Bacon B, Curry MP, Milligan S, Nwankwo CU, Tsai N, Younossi Z, Afdhal N
Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther. 2018 06; 47(11):1511-1522.
Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network.
Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep. 2004 Apr; 6(2):140-50.
Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes.
The natural history of hepatitis C. Semin Liver Dis. 2004; 24 Suppl 2:3-8.
Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004 Dec; 40(6):1450-8.
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
Hong Z, Chasan B, Bansil R, Turner BS, Bhaskar KR, Afdhal NH
Atomic force microscopy reveals aggregation of gastric mucin at low pH. Biomacromolecules. 2005 Nov-Dec; 6(6):3458-66.
Atomic force microscopy reveals aggregation of gastric mucin at low pH.
Martin CR, Blanco PG, Keach JC, Petz JL, Zaman MM, Bhaskar KR, Cluette-Brown JE, Gautam S, Sheth S, Afdhal NH, Lindor KD, Freedman SD
The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2012 Jan; 35(2):255-65.
The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.
Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL, Urban TJ, Shianna K, Fellay J, Goodman Z, Noviello S, Pedicone LD, Afdhal N, Sulkowski M, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci. 2012 Aug; 57(8):2213-21.
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.
Erratum to: The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection. Dig Dis Sci. 2012 Sep; 57(9):2479.
Erratum to: The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection.
Calcium augments binding of bilirubin to bovine gallbladder mucin. Hepatology. 1990; 12:899.
Calcium augments binding of bilirubin to bovine gallbladder mucin
Changqing Yang, Jiyao Wang, Michael Zeisberg, Mary Soubasakos, Nezam H Afdhal, Raghu Kalluri
Epithelial to Mesenchymal Transition During Liver Fibrosis. Hepatology. 2003; 38(4):332A.
Epithelial to Mesenchymal Transition During Liver Fibrosis
Paul J. Pockros, Mitchell L. Shiffman, Eugene R. Schiff, Nezam H. Afdhal, Mark S. Sulkowski, Zobair Younossi, Teresa Wright, Douglas T. Dieterich, Janice Jenkins, Gerhard J. Leitz, Peter J. Bowers
Long-term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV)Therapy. Gastroenterology. 2004; 126(4):A-720.
Long-term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV)Therapy
Nezam H. Afdhal, Douglas T. Dieterich, Paul J. Pockros, Eugene R. Schiff, Mitchell L. Shiffman, Mark S. Sulkowski, Teresa Wright, Zobair Younossi, Peter J. Bowers
Epoetin Alfa Treatment of Anemic HCV-infected Patients Allows for Maintenance of Ribavirin Dose, Increases Hemoglobin Levels, and Improves Quality of Life Vs Placebo: A Randomized, Double-blind, Multi-center Study. Gastroenterology. 2003; 124(4):A-714.
Epoetin Alfa Treatment of Anemic HCV-infected Patients Allows for Maintenance of Ribavirin Dose, Increases Hemoglobin Levels, and Improves Quality of Life Vs Placebo: A Randomized, Double-blind, Multi-center Study
Colorectal Cancer Screening, Core Curriculum in Medicine
Colorectal Cancer Screening, Core Curriculum in Medicine. 1997.
Eric J Lawitz, Norma S Cantu, Mitchell Davis, Nezam Afdhal, Michael Curry, Mark Mailliard, Frank AdamsNaoky TsaiTarun Kothari, K.P. Ganeshappa, James Cox, Bruce Silverman, Shailesh C Kadakia
Triple Therapy Compared to Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin for Treatment Naive Chronic Hepatitis C [Tri-Star Trial]: Final Results. Hepatology. 2003; 38(4):636-7A.
Triple Therapy Compared to Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin for Treatment Naive Chronic Hepatitis C [Tri-Star Trial]: Final Results
Vijayan Balan, Ira M Jacobson, Robert Brown, Jr., Nezam Afdhal, R Rubin, James Spivey, Bradley Freilich, David E Bernstein, Virender Sharma, Clifford Brass, WIN-R Study Group
Regional and Racial Variation of Hepatitis C Genotypes in the United States. Hepatology. 2002; 36(4):711A.
Regional and Racial Variation of Hepatitis C Genotypes in the United States
TNF-a stimulates mucin secretion, but not mucin synthesis in human gallbladder epithelial cells. Gastroenterology. 1998; (114):1238A.
TNF-a stimulates mucin secretion, but not mucin synthesis in human gallbladder epithelial cells
Afdhal NH, Ostrow JD, Koehler R, Niu N, Groen AK, Veis A, Nunes DP, Offner GD
Interaction of bovine gallbladder mucin and calcium-binding protein: effects on calcium phosphate precipitation. Gastroenterology. 1995 Nov; 109(5):1661-72.
Interaction of bovine gallbladder mucin and calcium-binding protein: effects on calcium phosphate precipitation.
Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest. 1995 Nov; 96(5):2311-21.
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.
Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-Kafrawy S, Mikhail N, Magder LS, Afdhal NH, Strickland GT
Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007 Apr; 46(4):620-7.
Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C.
Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010 Apr; 50(4):434-49.
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul; 139(1):120-9.e18.
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
Klibansky DA, Mehta SH, Curry M, Nasser I, Challies T, Afdhal NH
Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat. 2012 Feb; 19(2):e184-93.
Transient elastography for predicting clinical outcomes in patients with chronic liver disease.
Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, Horsburgh R, Craven D, Sherman KE, Koziel MJ
Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology. 2004 Jul; 40(1):125-32.
Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV.
Maintenance therapy for chronic hepatitis C. Curr Gastroenterol Rep. 2005 Feb; 7(1):50-3.
Maintenance therapy for chronic hepatitis C.
Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006 Aug; 131(2):470-7.
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
Afdhal NH, Flamm S, Imperial JA, Malet PF, Tong M, Pappas SC, Campagna J
Digestive Disease Week Presentation in Atlanta, Ga
Pegylated (40kDa) Interferon Alfa-2a (PEGASYS) in Combination with Ribavirin , Mycophenolate Mofetil, Amantadine, or Amantadine plus Ribavirin in Patients that did not Respond to Rebetron Therapy: A Preliminary Report of a Randomized , Multicenter Study. Digestive Disease Week Presentation in Atlanta, Ga. 2001.
Pegylated (40kDa) Interferon Alfa-2a (PEGASYS) in Combination with Ribavirin , Mycophenolate Mofetil, Amantadine, or Amantadine plus Ribavirin in Patients that did not Respond to Rebetron Therapy: A Preliminary Report of a Randomized , Multicenter Study
Popov Y, Zaks J, Grall F, Liebermann T, Afdhal NH, Schuppan D
T Cell Derived Membrane Microparticles containing Emmprin Induce Profibrolytic Activation in Hepatic Stellate Cells. Hepatology. 2008; 46:717A.
T Cell Derived Membrane Microparticles containing Emmprin Induce Profibrolytic Activation in Hepatic Stellate Cells
Keaveny A, Cardenas A, Nunes DP, Edge AE, Afdhal NH
Peripheral TH1 and TH2 cytokine responses in patients with HCV treated with interferon and interferon-ribavirin. Hepatology. 1999; (30):356A.
Peripheral TH1 and TH2 cytokine responses in patients with HCV treated with interferon and interferon-ribavirin
Eliot Godofsky, Nezam Afdhal, Vinod Rustgi, Lawton Shick, Lael Duncan, Xiao-Jian Zhou, George Chao, Christopher Fang, Barbara Fielman, Maureen Myers, Nathaniel Brown
A Phase I/II Dose Escalation Trial Assessing Tolerance, Pharmacokinetics, and Antiviral Activity of NM283, a Novel Antiviral Treatment for Hepatitis C. Gastroenterology. 2004; 126(4):A-681.
A Phase I/II Dose Escalation Trial Assessing Tolerance, Pharmacokinetics, and Antiviral Activity of NM283, a Novel Antiviral Treatment for Hepatitis C
Reduced sensitivity of HCV genotype 3 to interferon when co-infected with genotype 1. Gastroenterology. 1998; (114):1314A.
Reduced sensitivity of HCV genotype 3 to interferon when co-infected with genotype 1
Nezam H. Afdhal, Hiro Masuzaki, Bradley Turner, Imad Nasser, Jeffrey Flier
Transgenic Mice with 11 Beta-Hydroysteroid Dehydrogenase Type 1 Overexpression in Adipocytes Develop Fatty Liver Disease. Hepatology. 2002; 36(4):216A.
Transgenic Mice with 11 Beta-Hydroysteroid Dehydrogenase Type 1 Overexpression in Adipocytes Develop Fatty Liver Disease
Furqaan Ahmed, Ira M. Jacobson, Robert S. Brown, Jr., Nezam Afdhal, Raymond Rubin, James Spivey, Bradley Freilich, Frederic Regenstein, David Bernstein, Robert Doig, Clifford Brass, WIN-R Study Group
Clinical Significance of Pegylated Interferon Induced Neutropenia: Results from the WIN-R Trial. Gastroenterology. 2003; 124(4):A-700.
Clinical Significance of Pegylated Interferon Induced Neutropenia: Results from the WIN-R Trial
Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol. 2007 Apr; 46(4):543-5.
Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis.
Shah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):255-8.
Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases.
Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology. 2003 May; 37(5):972-4.
Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?
Leahy J, O'Leary A, Afdhal N, Gray E, Milligan S, Wehmeyer MH, Walsh C
The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection. Res Synth Methods. 2018 Sep; 9(3):441-469.
The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection.
The Non-responding Hepatitis C Patient: Options and Variables, B. Bacon, Ed.
Options for Non-responders to Combination Therapy. The Non-responding Hepatitis C Patient: Options and Variables, B. Bacon, Ed. 2000; 15-28.
Options for Non-responders to Combination Therapy
Substance P is not a neuromediator of splanchnic hyperemia or portal hypertension in the cirrhotic rat. Gastroenterology. 1997; (112):1324A.
Substance P is not a neuromediator of splanchnic hyperemia or portal hypertension in the cirrhotic rat
N. Afdhal, M Rodriguez-Torres, E. Lawitz, E. Godofsky, G. Chao, B. Fielman, S Knox, M. Brown, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Fundacion de Investigacion de Diego, Santurce, PR, USA; Alamo medical Research, San Antonio, TX, USA; Bach & Godofsky, Bradenton, FL, USA; Idenix Pharmaceuticals, Cambridge, MA, USA
Enhanced Antiviral Efficacy For Valopicitabine (NM283) Plus Peg-Interferon in Hepatitis C Patients With HCV Genotype-1 Infection: Results of a Phase IIa Multicenter Trial. Journal of Hepatology. 2005; 42(2):39-40.
Enhanced Antiviral Efficacy For Valopicitabine (NM283) Plus Peg-Interferon in Hepatitis C Patients With HCV Genotype-1 Infection: Results of a Phase IIa Multicenter Trial
Effect of mucus gel layer on phospholipid transfer across human cultured gallbladder epithelia. Hepatology. 1994; (20):115.
Effect of mucus gel layer on phospholipid transfer across human cultured gallbladder epithelia
Clinical features and diagnosis of acute cholecystitis
Clinical features and diagnosis of acute cholecystitis. 1998.
Valerie Byrnes, Anne Miller, Cheryl Weinstein, Erin Hill, Robert Lenkinski, David Alsop, Nezam H. Afdhal
Cerebral Metabolic and neuropsychiatric effects of pegylated interferon (PIFN) therapy in Hepatitis C. Gastroenterology. 2005; 128(4):p-22.
Cerebral Metabolic and neuropsychiatric effects of pegylated interferon (PIFN) therapy in Hepatitis C
The Blockade of Estrogen Action by Fulvestrant (ICI 182,780) Prevents Cholesterol Gallstone Formation in the Mouse. Hepatology. 2003; 38(4):195A.
The Blockade of Estrogen Action by Fulvestrant (ICI 182,780) Prevents Cholesterol Gallstone Formation in the Mouse
Offner GD, Nunes DP, Zhang F, McAnany DB, Afdhal NH
Alterations in gallbladder mucin gene expression in patients with cholesterol gallstones. Gastroenterology. 1996; (110):1282A54.
Alterations in gallbladder mucin gene expression in patients with cholesterol gallstones
Computers in Gastroenterology Vickery R, Editor
A Colorectal Cancer Database. Computers in Gastroenterology Vickery R, Editor. 1988.
Abnormal liver function tests for the Primary Care Physician, Core Curriculum in Medicine
Abnormal liver function tests for the Primary Care Physician, Core Curriculum in Medicine. 1997.
Byrnes,VM, Miller, A, Hill,E, Weinstein, david Alsop, Lenkinski, R.E, Afdhal, NH,
The Cerebral Metabolic and Cognitive Effects of Pegylated interferon (PIFN) and Hepatitis C Viral (HCV) Clearance. Hepatology. 2007; 46:380A.
The Cerebral Metabolic and Cognitive Effects of Pegylated interferon (PIFN) and Hepatitis C Viral (HCV) Clearance
Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin Trials. 2012 Feb; 9(1):102-12.
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.
Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J Lipid Res. 2004 Mar; 45(3):438-47.
Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation.
Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005 Jul; 43(1):78-84.
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.
Goodman ZD, Becker RL, Pockros PJ, Afdhal NH
Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007 Apr; 45(4):886-94.
Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis.
Shah MB,Brown RS, Barski T, Freilich B, Levine RA, Afdhal NH
Tolerability of low-dose peginterferon alfa-2B in hepatitis C patients with Cirrhosis: Results from the copilot trial. Hepatology. 2007; 46:825A.
Tolerability of low-dose peginterferon alfa-2B in hepatitis C patients with Cirrhosis: Results from the copilot trial
Eric J. Lawitz, Norma S. Cantu, Stephen A. Harrison, Shailesh Kadakia, Frank Adams, Mitchell Davis, Richard Sperling, Naoky Tsai, Andrei Gasic, Tarum Kothari, K.P. Ganeshappa, James Cox, Barry Sanders, Bruce Silverman, Elias Ghandour, Jeffrey Medoff, Nezam Afdhal, Mark Mailliard, Michael Curry, Alamo Study Group
The Outcome of Hepatitis C Therapy in African Americans and Hispanics with Persistently Normal Transaminases. Gastroenterology. 2004; 126(4):A-696.
The Outcome of Hepatitis C Therapy in African Americans and Hispanics with Persistently Normal Transaminases
Therapeutic strategies for chronic hepatitis B virus infection in 2008. Am J Med. 2008 Dec; 121(12 Suppl):S33-44.
Therapeutic strategies for chronic hepatitis B virus infection in 2008.
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM
Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010 Apr 08; 362(14):1292-303.
Telaprevir for previously treated chronic HCV infection.
Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018 10; 155(4):1140-1153.
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Eliot Godofsky, Bach & Godofsky, Brandenton, FL; Jules Dienstag, Massachusetts general Hospital, Boston MA; Vinod Rustgi, Metropolitan Research, Fairfax, VA; Lawton Schick, University of Massachusetts Health Center, Worcester, MA; David McEniry, Northwest Medical Specialties, PLLC, Tacoma, WA; Xiao-Jian Zhou, George Chao, Christopher Fang, Barbara Fielman, Maureen Myers, Nathaniel Brown, Idenix Pharmaceuticals, Cambridge, MA
Final phase I/II trial results for NM283, A new polymerase inhibitor for Hepatitis C: Antiviral efficancy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology. 2004; 40(4):726A.
Final phase I/II trial results for NM283, A new polymerase inhibitor for Hepatitis C: Antiviral efficancy and tolerance in patients with HCV-1 infection, including previous interferon failures
McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29; 357(22):2227-36.
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, Moore RD, Afdhal NH, Thomas DL
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007 Oct 18; 21(16):2209-16.
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, Patel K, Harrison SA, Urban TJ, Naggie S, Fellay J, Tillmann HL, Shianna K, Noviello S, Pedicone LD, Esteban R, Kwo P, Sulkowski MS, Afdhal N, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat. 2012 May; 19(5):332-40.
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
Journal of the Irish Colleges of Physicians and Surgeons
New Perspectives on Gallstone Pathogenesis and Prevention. Journal of the Irish Colleges of Physicians and Surgeons. 1995; 24:267-78.
New Perspectives on Gallstone Pathogenesis and Prevention
Brett D. Kalmowitz, Lorenzo Rossaro, Howard P. Monsour Jr., Robert S. Brown Jr., Mohamad A. El-Kurdi, K.R. Bhaskar, Nezam H. Afdhal
Des-Gamma Carboxyprothrombin (PIVKA-II)and Alfafetoprotein in Cirrhosis Secondary to HCV. Gastroenterology. 2004; 126(4):A-679.
Des-Gamma Carboxyprothrombin (PIVKA-II)and Alfafetoprotein in Cirrhosis Secondary to HCV
Noah T. Zinkin, Beth Israel Deaconess Medical Center, Boston, MA; Hasan H. Otu, Dimitrios Spentzos, Manuel Aivado, Meghan Wells, Beth Israel Deaconess Medical Center, proteomics Core, Boston, MA; Brett D. Kalmowitz, K.R. Bhaskar, Beth Israel Deaconess Medical Center, Boston, MA; Towia A. Libermann, Beth Israel Deaconess Medical Center, Proteomics Core, Boston, MA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA
A Combined Proteomic and Serologic approach to Diagnosis of Hepatocellular Carcinoma. Hepatology. 2005; vol. 42(no. 4):72A.
A Combined Proteomic and Serologic approach to Diagnosis of Hepatocellular Carcinoma
Eugene R Schiff, Paul Pockros, Mitchell L Shiffman, John McHutchison, Robert Gish, Nezam H Afdhal, Manana Makhviladze, Mira Huyghe, David Hecht, Tilman Oltersdorf, David A. Shapiro
Oral IDN-6556, An Anti-Apoptotic Caspase Inhibitor, Lowers Aminotransferases in HCV Patients. Gastroenterology. 2004; 126(4):A-668.
Oral IDN-6556, An Anti-Apoptotic Caspase Inhibitor, Lowers Aminotransferases in HCV Patients
Nunes DP, Thim L, Niu N, Afdhal NH, Offner GD
Human spasmolytic polypeptide (hSP) significantly enhances the cholesterol crystal nucleating properties of mucin. Gastroenterology. 1998; (114):1313A.
Human spasmolytic polypeptide (hSP) significantly enhances the cholesterol crystal nucleating properties of mucin
Kenney TJ, Stefan A, Nunes DP, Offner GD, Nikulasson S, Pouthalakis C and Afdhal NH
Effect of substance P and its receptor antagonist CP-96,345 on systemic arterial and portal pressure in normal and cirrhotic rats. Hepatology. 1995; (22):258.
Effect of substance P and its receptor antagonist CP-96,345 on systemic arterial and portal pressure in normal and cirrhotic rats
Xiao-Jian Zhou, Idenix Pharmaceuticals, Inc., Cambridge, MA; Maribel Rodiguez-Torres, Funacion de Investigacion de Diego, Santurce; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Eliot Godofsky, Bach & Godofsky, Bradenton, FL; Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Barbara Fielman Constance, George Chao, Steven Knox, Nathaniel A. Brown, Idenix Pharmaceuticals, Cambridge, MA
Asence of effect of Pegylated interferon Alfa-2B on the pharmacokenetics of valopicitabine (NM283) in patients with chronic hepatitis C. Hepatology. 2005; 42(4):148A.
Asence of effect of Pegylated interferon Alfa-2B on the pharmacokenetics of valopicitabine (NM283) in patients with chronic hepatitis C
Non-invasive markers of hepatic fibrosis
Non-invasive markers of hepatic fibrosis. 2000.
Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH
Clinical cancer research : an official journal of the American Association for Cancer Research
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008 Jan 15; 14(2):470-7.
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 2010 Jul; 30(6):795-808.
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis.
Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012 Mar; 56(3):571-8.
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
Kornek M, Lynch M, Mehta SH, Lai M, Exley M, Afdhal NH, Schuppan D
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology. 2012 Aug; 143(2):448-58.
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.
Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol. 2018 12; 69(6):1365-1370.
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology. 2019 02; 69(2):684-698.
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
John G. McHutchinson, Duke Univ, Durham, NC; Bruce R. Bacon, St. Louis Univ Hopsital, St. Louis, MO; Stuart C. Gordon, Henry Ford Hospital, Detroit, MI; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Mitchell Shiffman, Medical College of Richmond Virginia, Richmond, VA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira M. Jacobson, Cornell Univ, New York, NY; Andrew Muir Duke University, Durham, NC; Susan M. Efler, A. Vicari, K. Myette, Nav Ahluwalia, P.P. Murzenok Coley Pharmalbach, Art M. Krieg, Coley Pharmaceutical Group, Ottawa, Canada
Immunophenotyping profile of CPG 10101, a new TLR9 agonist antiviral for hepatitis C. Hepatology. 2005; 42(4):148A.
Immunophenotyping profile of CPG 10101, a new TLR9 agonist antiviral for hepatitis C
Eric J Lawitz, Norma S Cantu, Mitchell Davis, Nezam Afdhal, Michael Curry, Mark Mailliard, Frank Adams, Naoky Tsai, Andrei Gasic, Tarun Kothari, K.P. Ganeshappa, James Cox, Bruce Silverman, Shailesh C Kadakia
Triple Therapy Compared to Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin for Previous Nonresponders and Relapsers with Chronic Hepatitis C. Hepatology. 2003; 38(4):742A.
Triple Therapy Compared to Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin for Previous Nonresponders and Relapsers with Chronic Hepatitis C
Gastrointestinal Infections LaMont JT, Ed.
Small Bowel and Colonic Infections in AIDS Patients. Gastrointestinal Infections LaMont JT, Ed. 1997; 191-247.
Small Bowel and Colonic Infections in AIDS Patients
John G McHutchison, Duke University, Durham, NC; Bruce R Bacon, Saint Louis University School of Medicine, Saint Louis MO; Stuart C Gordon, William Beaumont Hospital, Royal Oak, MI; Nezam H Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira M Jacobson, Cornell University, New York, NY; Andrew Muir, Duke Univeristy, Durham, NC; Arthur M Krieg, Susan Efler, Mohammed Al-Adhami, Heather L Davis, Tess K Schmalback, Coley Pharmaceutical Group, Inc. Wellesley, MA
Hepatology The official Journal of the American Association for the Study of Liver Disease
Human pharmacological activity of a new TLR9 agonist antiviral, CPG 10101 (Actilon). Hepatology The official Journal of the American Association for the Study of Liver Disease. 2004; 40(4):697A.
Human pharmacological activity of a new TLR9 agonist antiviral, CPG 10101 (Actilon)
Stephen A. Harrison, Chris Fincke, Sangik Oh, Thomas Kelleher, Katie Smith, Nezam Afdhal
Combined Serological and clinical measures enhance the non-invasive diagnosis of advanced fibrosis in NAFLD. Gastroenterology. 2005; 128(4):p-227.
Combined Serological and clinical measures enhance the non-invasive diagnosis of advanced fibrosis in NAFLD
The American journal of gastroenterology
Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade. Am J Gastroenterol. 2011 Dec; 106(12):2121-2.
Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade.
Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis. Antivir Ther. 2010; 15(3):281-91.
Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis.
Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010 Nov; 139(5):1602-11, 1611.e1.
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
Tapper EB, Cohen EB, Patel K, Bacon B, Gordon S, Lawitz E, Nelson D, Nasser IA, Challies T, Afdhal N
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2012 Aug; 10(8):932-937.e1.
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.
Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice. Gastroenterol Hepatol (N Y). 2011 Mar; 7(3 Suppl 4):1-16.
Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice.
HIV Infection: A Clinical Manual Libman H, Witzburg RA, Eds.
Gastrointestinal Manifestations of AIDS. HIV Infection: A Clinical Manual Libman H, Witzburg RA, Eds. 1996; 165-80.
X.J. Zhou, N. Afdhal, E Godofsky, J. Dienstag, V. Rustgi, L. Schick, D. McInery, B.A. Fielman, N.A. Brown. Idenix Pharmaceuticals, Inc, Cambridge, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA; Bach & Godofsky, Bradenton, FL, USA; Massachusetts general Hospital, Boston, MA, USA; Metropolitan Research, Fairfax, VA, USA; University of Massachusetts Health Center, Worcester, MA, USA; Northwest Medical Specialties, Tacoma, WA, USA
Pharmacokinetics and Pharmacodynamics of Valopicitabine(NM283), A New Nucleoside HCV Polymerase Inhibitor: Results from a phase I/II Dose-Escalation Trial in Patients with HCV-1 Infection. Journal of Hepatology. 2005; 42(4):229.
Pharmacokinetics and Pharmacodynamics of Valopicitabine(NM283), A New Nucleoside HCV Polymerase Inhibitor: Results from a phase I/II Dose-Escalation Trial in Patients with HCV-1 Infection
Advances in Digestive Diseases. Editor: Howden CW
Noninvasive markers of Liver fibrosis. Advances in Digestive Diseases. Editor: Howden CW. 2007; 121 - 134.
Cecils Textbook of Medicine Goldman L, Ed.
Diseases of the Gallbladder and Bile Ducts. Cecils Textbook of Medicine Goldman L, Ed. 2003.
Diseases of the Gallbladder and Bile Ducts
Celli J, Gregor B, Turner B, Afdhal NH, Bansil R, Erramilli S
Viscoelastic properties and dynamics of porcine gastric mucin. Biomacromolecules. 2005 May-Jun; 6(3):1329-33.
Viscoelastic properties and dynamics of porcine gastric mucin.
Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology. 2006 Oct; 44(4):925-35.
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection.
Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH
The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007 Dec; 47(6):760-7.
The clinical significance of persistently normal ALT in chronic hepatitis B infection.
Complications of laparoscopic cholecystectomy
Complications of laparoscopic cholecystectomy. 1997.
Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Nunes DP, Keates AC, Afdhal NH, Offner GD
Bovine gall-bladder mucin contains two distinct tandem repeating sequences: evidence for scavenger receptor cysteine-rich repeats. Biochem J. 1995 Aug 15; 310 ( Pt 1):41-8.
Bovine gall-bladder mucin contains two distinct tandem repeating sequences: evidence for scavenger receptor cysteine-rich repeats.
Afdhal NH, Gong D, Niu N, Turner B, LaMont JT, Offner GD
Cholesterol cholelithiasis in the prairie dog: role of mucin and nonmucin glycoproteins. Hepatology. 1993 Apr; 17(4):693-700.
Cholesterol cholelithiasis in the prairie dog: role of mucin and nonmucin glycoproteins.
Early TIPS to improve survival in acute variceal bleeding. N Engl J Med. 2010 Jun 24; 362(25):2421-2.
Early TIPS to improve survival in acute variceal bleeding.
Afdhal NH, Kelly J, McCormick PA, O'Donoghue DP
JPEN. Journal of parenteral and enteral nutrition
Remission induction in refractory Crohns disease using a high calorie whole diet. JPEN J Parenter Enteral Nutr. 1989 Jul-Aug; 13(4):362-5.
Remission induction in refractory Crohns disease using a high calorie whole diet.
Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012 May; 19 Suppl 2:1-26.
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Cao X, Niu N, Offner GD, Nunes D, Bansil R, Wolf DE, Afdhal NH
Mucin vesicle interactions are biphasic and depend on mucin glycosylated and non-glycosylated structural domains. Gastroenterology. 1997; (112):1237A.
Mucin vesicle interactions are biphasic and depend on mucin glycosylated and non-glycosylated structural domains
Clinicians Companion I&II: Management of Hepatitis C
Clinicians Companion I&II: Management of Hepatitis C. 1998.
Nunes DP, Keaveny A, Gunsalus R, Lebel MD, Edge ASB, Offner GD, Afdhal NH
Serum cytokine profiles in patients with chronic HCV: Effect of interferon treatment. Hepatology. 1998; (28):364A.
Serum cytokine profiles in patients with chronic HCV: Effect of interferon treatment
Clinical Implications: Hepatitis in the New Millenium. Predictors of response to HCV
Clinical Implications: Hepatitis in the New Millenium. Predictors of response to HCV. 2001.
Eltrombopag in patients with chronic liver disease. Expert Opin Pharmacother. 2013 Apr; 14(5):669-78.
Eltrombopag in patients with chronic liver disease.
Offner GD, Nunes DP, Moore EW, Afdhal NH
Prostaglandin E1 stimulates mucin secretion and increases MUC3 mRNA levels in cultured human gallbladder epithelial cells. Hepatology. 1995; (22):110.
Prostaglandin E1 stimulates mucin secretion and increases MUC3 mRNA levels in cultured human gallbladder epithelial cells
Michael Zeisberg, Kyle Kramer, Changqing Yang, Nazia Akhtar, Nezam Afdhal, Raghu Kalluri
Liver Fibrosis: Extracellular Matrix Microenvironment Regulates Hepatocyte Behavior. Hepatology. 2002; 36(4):489A.
Liver Fibrosis: Extracellular Matrix Microenvironment Regulates Hepatocyte Behavior
Chronic Viral Hepatitis; Diagnosis and Therapeutics, Wu GY, Koff RS, Eds.
Management of the Patient with Chronic Hepatitis. Chronic Viral Hepatitis; Diagnosis and Therapeutics, Wu GY, Koff RS, Eds. 2001; 211-32.
Management of the Patient with Chronic Hepatitis
Sanaa Kamal, Ahmed Al Tawil, Qi HE, Khalifa Sayed, Kheiry El Naggar, Sarah Hakam, Wafaa Saleh, Manal El Sayed, Leonardo Bianchi, Mohamed Madwar, Nezam Afdhal
Long term cohort study of the clinical and histologicalprogression of HCV. Gastroenterology. 2005; 128(4):p-195.
Long term cohort study of the clinical and histologicalprogression of HCV
Nunes DP, Anastopolous H, Gordon F, Chopra S, Petruff C, Salomons H, Wilson S, Afdhal NH
Double blind placebo controlled study of interferon versus interferon plus ribavirin for the treatment of hepatitis C in patients who previously failed interferon monotherapy. Hepatology. 1999; (30):199A.
Double blind placebo controlled study of interferon versus interferon plus ribavirin for the treatment of hepatitis C in patients who previously failed interferon monotherapy
An unusual cause of abdominal pain in a patient with hepatitis C cirrhosis. Gut. 2005 Apr; 54(4):460, 521.
An unusual cause of abdominal pain in a patient with hepatitis C cirrhosis.
Changqing Yang, Hikaru Sugimoto, Mauricio Giraldo, Nezam Afdhal, Michael Zeisberg, Raghu Kalluri
Bone Morphogenic Protein-7, a Member of the TGF-Beta Superfamily, Accelerates Liver Regeneration After Partial Hepatectomy in Mice. Hepatology. 2002; 36(4):470A.
Bone Morphogenic Protein-7, a Member of the TGF-Beta Superfamily, Accelerates Liver Regeneration After Partial Hepatectomy in Mice
Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, Kelly CP, Ewoldt RH, McKinley GH, So P, Erramilli S, Bansil R
Proceedings of the National Academy of Sciences of the United States of America
Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A. 2009 Aug 25; 106(34):14321-6.
Helicobacter pylori moves through mucus by reducing mucin viscoelasticity.
Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018 Dec; 2(12):1467-1478.
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease.
Nunes D, Sharma A, Cohen S, Rea C, Offner GD, Apstein M, Afdhal NH
Randomized trial of interferon dose escalation for the treatment of chronic hepatitis C. Gastroenterology. 1996; (110):1281A.
Randomized trial of interferon dose escalation for the treatment of chronic hepatitis C
Cholangitis in the immunosuppressed patient (AIDS Cholangiopathy)
Cholangitis in the immunosuppressed patient (AIDS Cholangiopathy). 1999.
Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L, Houghton M, Walker BD, Koziel MJ
Journal of immunology (Baltimore, Md. : 1950)
Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol. 1998 Feb 01; 160(3):1479-88.
Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.
The not so good effects of nitric oxide inhibition with methylene blue in cirrhosis and ascites. Dig Dis Sci. 2007 Apr; 52(4):939-40.
The not so good effects of nitric oxide inhibition with methylene blue in cirrhosis and ascites.
Kanwal F, Befeler A, Chari RS, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, Schwartz J, VanThiel D, Li J, Zeringue A, Di'Bisceglie A
Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network. Aliment Pharmacol Ther. 2012 Aug; 36(3):257-65.
Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network.
Michelle Lai, Benjamin Hyatt, BIDMC, Boston, MA; Nezam Afdhal, BIDMC, Boston, MA
Role of liver Biopsy in Patients with Normal ALT and High HBV DNA. Hepatology. 2005; 42(4):188A.
Role of liver Biopsy in Patients with Normal ALT and High HBV DNA
Changqing Yang, Michael Zeisberg, Nezam Afdhal, Raghu Kalluri
New Insights into the Migratory Behavior of Human Hepatocellular Carcinoma HEPG2 Cells. Hepatology. 2002; 36(4):449A.
New Insights into the Migratory Behavior of Human Hepatocellular Carcinoma HEPG2 Cells
Ira Jacobson, Robert S Brown, Jr., Nezam Afdhal, Raymond Rubin, James Spivey, Bradley Freilich, Frederic Regenstein, David Bernstein, Robert Doig, Clifford Brass
Characterictics of HCV Infection in African-Americans: Findings from the WIN-R Trial. Hepatology. 2002; 36(4):377A.
Characterictics of HCV Infection in African-Americans: Findings from the WIN-R Trial
Afdhal NH, Levine R, Brown R Jr.,Freilich B, O'brien M, Brass C
Colchicine Versus Peg-Interferon Alfa 2B long term Therapy: Results of the 4 year copilot trial. Hepatology. 2008; 48:S4.
Colchicine Versus Peg-Interferon Alfa 2B long term Therapy: Results of the 4 year copilot trial
HIV Infection: A Clinical Manual Libman H, Witzburg R, Eds.
Gastrointestinal manifestations of the Acquired Immunodeficiency Syndrome. HIV Infection: A Clinical Manual Libman H, Witzburg R, Eds. 1993; 146-159.
Gastrointestinal manifestations of the Acquired Immunodeficiency Syndrome
Asim Khokhar, Rory farnan, Chelsea MacFarlane, BIDMC, Boston, MA; Bruce Bacon, SLU, St. Louis, MO; John McHutchison, Duke Univ medical center, Durham, NC; Nezam Afdhal, beth Israel Deaconess medical Center, Boston, MA
Liver Stiffness and biomarkers: Correlation with cirrhosis, protal hypertension and hepatic synthetic function. hepatology. 2005; 42(4):112A.
Liver Stiffness and biomarkers: Correlation with cirrhosis, protal hypertension and hepatic synthetic function
Biliary Tract Disease. Primary Care Medicine Noble J, Ed. 2001; 920-7.
Helen H. Wang, Nezam H. Afdhal, David Q. Wang
Impaired Gallbladder motility and accelerated cholesterol crystallization and Gallstone formation in mice overexpressing human mucin gene 1 (hmuc1). Gastroenterology. 2005; 128(4):p-103.
Impaired Gallbladder motility and accelerated cholesterol crystallization and Gallstone formation in mice overexpressing human mucin gene 1 (hmuc1)
Afdhal NH, Niu N, Nunes D, Bansil R, Gantz D, Small DM, Offner GD
Molecular basis of nucleation: differences between slow and fast pro-nucleating proteins. Gastroenterology. 1993; (104):867.
Molecular basis of nucleation: differences between slow and fast pro-nucleating proteins
Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019 10; 70(4):1336-1348.
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019 12; 70(6):1913-1927.
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Gastroenterology clinics of North America
Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019 06; 48(2):281-289.
Associate Professor of Medicine, Part-time
Sasaki R, Shiino C, Imawari M, Bentley R, Cai B, Yoshida M, Afdhal N
Hepatology research : the official journal of the Japan Society of Hepatology
Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Hepatol Res. 2019 Oct; 49(10):1169-1181.
Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance.
Hepatitis C viral infection in difficult-to-treat populations: An overview. Clin Liver Dis (Hoboken). 2012 Jul; 1(3):63-64.
Hepatitis C viral infection in difficult-to-treat populations: An overview.
Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology. 2019 11; 70(5):1521-1530.
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
Tsai N, Bacon B, Curry M, Flamm SL, Milligan S, Wick N, Younossi Z, Afdhal N
Changing demographics among populations prescribed HCV treatment, 2013-2017. Am J Manag Care. 2019 07; 25(7):319-323.
Changing demographics among populations prescribed HCV treatment, 2013-2017.
Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, Abutidze A, Sharvadze L, Kerashvili V, Butsashvili M, Metreveli D, Gvinjilia L, Shadaker S, Nasrullah M, Adamia E, Zeuzem S, Afdhal N, Arora S, Thornton K, Skaggs B, Kuchuloria T, Lagvilava M, Sergeenko D, Averhoff F
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018. Clin Infect Dis. 2020 08 22; 71(5):1263-1268.
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
Navarro VJ, Belle SH, D'Amato M, Afdhal N, Brunt EM, Fried MW, Rajender Reddy K, Wahed AS, Harrison S
Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One. 2019; 14(10):e0223915.
Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
Ezaz G, Trivedi HD, Connelly MA, Filozof C, Howard K, L Parrish M, Kim M, Herman MA, Nasser I, Afdhal NH, Jiang ZG, Lai M
Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD. Hepatol Commun. 2020 May; 4(5):670-680.
Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD.
Giannini EG, Kano T, Ochiai T, Bentley R, Shrestha P, Afdhal N
European journal of clinical investigation
Bleeding events in lusutrombopag-treated thrombocytopenic patients. Eur J Clin Invest. 2021 Jun; 51(6):e13503.
Bleeding events in lusutrombopag-treated thrombocytopenic patients.
Curry MP, Flamm SL, Milligan S, Tsai N, Wick N, Younossi Z, Afdhal NH
Journal of managed care & specialty pharmacy
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. J Manag Care Spec Pharm. 2021 Sep; 27(9):1239-1248.
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.
Åberg F, Danford CJ, Thiele M, Talbäck M, Rasmussen DN, Jiang ZG, Hammar N, Nasr P, Ekstedt M, But A, Puukka P, Krag A, Sundvall J, Erlund I, Salomaa V, Stål P, Kechagias S, Hultcrantz R, Lai M, Afdhal N, Jula A, Männistö S, Lundqvist A, Perola M, Färkkilä M, Hagström H
A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. Hepatol Commun. 2021 Jun; 5(6):1021-1035.
A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease.
Hakim A, Moll M, Brancale J, Liu J, Lasky-Su JA, Silverman EK, Vilarinho S, Jiang ZG, Pita-Juárez YH, Vlachos IS, Zhang X, Åberg F, Afdhal NH, Hobbs BD, Cho MH
Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury. Hepatology. 2021 12; 74(6):3394-3408.
Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.
Bosch J, Chung C, Carrasco-Zevallos OM, Harrison SA, Abdelmalek MF, Shiffman ML, Rockey DC, Shanis Z, Juyal D, Pokkalla H, Le QH, Resnick M, Montalto M, Beck AH, Wapinski I, Han L, Jia C, Goodman Z, Afdhal N, Myers RP, Sanyal AJ
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology. 2021 12; 74(6):3146-3160.
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG
Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology. 2022 04; 75(4):968-982.
Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis.
Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2022 05; 75(5):1235-1246.
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Tiwari-Heckler S, Yee EU, Yalcin Y, Park J, Nguyen DT, Gao W, Csizmadia E, Afdhal N, Mukamal KJ, Robson SC, Lai M, Schwartz RE, Jiang ZG
Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. Cell Rep. 2021 10 26; 37(4):109897.
Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease.
Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, Lai M
Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun. 2022 04; 6(4):765-779.
Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD.
Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, Lai M
Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2022 03 01; 117(3):453-461.
Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease.
Pan CQ, Afdhal NH, Ankoma-Sey V, Bae H, Curry MP, Dieterich D, Frazier L, Frick A, Hann HW, Kim WR, Kwo P, Milligan S, Tong MJ, Reddy KR
First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun. 2022 08; 6(8):1881-1894.
First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Yuen MF, Chen CY, Liu CJ, Jeng WJ, Elkhashab M, Coffin CS, Kim W, Greenbloom S, Ramji A, Lim YS, Kim YJ, Fung SK, Kim DJ, Jang JW, Lee KS, Iyer RP, Macfarlane C, Jackson K, Locarnini SA, Chan HLY, Afdhal NH
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B. Liver Int. 2023 01; 43(1):77-89.
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW, Okanoue T, Romero-Gómez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison S, Younossi ZM, Myers RP
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. 2023 03; 72(3):581-589.
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Kirmaier A, Kubiak J, Mahler L, Qian X, Wu L, Ono Y, Riedel S, Medline A, Yang X, Elamin S, Afdhal N, Arnaout R
Diagnostic microbiology and infectious disease
Case report and mini-review: Sarcina ventriculi in the stomach of an 80-year-old female. Diagn Microbiol Infect Dis. 2024 Feb; 108(2):116137.
Case report and mini-review: Sarcina ventriculi in the stomach of an 80-year-old female.
Curry MP, Tam E, Schneider C, Abdelgelil N, Hassanien T, Afdhal NH
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study. Int J Hepatol. 2024; 2024:8877130.
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study.
Loomba R, Ramji A, Hassanein T, Yoshida EM, Pang E, Schneider C, Curry MP, Afdhal NH
Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD. Hepatol Commun. 2024 04 01; 8(4).
Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD.
Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013 May; 13(5):401-8.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15; 381(9883):2100-7.
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Honarvar M, Lobo J, Schneider C, Wolfe N, Gawrieh S, Loomba R, Ramji A, Hassanein T, Yoshida EM, Pang E, Curry MP, Afdhal NH
Deep Learning Based Shear Wave Detection and Segmentation Tool for Use in Point-of-Care for Chronic Liver Disease Assessments. Ultrasound Med Biol. 2024 12; 50(12):1812-1820.
Deep Learning Based Shear Wave Detection and Segmentation Tool for Use in Point-of-Care for Chronic Liver Disease Assessments.
Lai M, Dillon ST, Gu X, Morhardt TL, Xu Y, Chan NY, Xiong B, Can H, Ngo LH, Jin L, Zhang X, Moreira CC, Leite NC, Villela-Nogueira CA, Otu HH, Schattenberg JM, Schuppan D, Afdhal NH, Libermann TA
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis. Hepatol Commun. 2024 Dec 01; 8(12).
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis.
Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013 Oct; 20(10):669-77.
Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.
Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM
Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. J Pediatr. 2013 Oct; 163(4):1058-64.e2.
Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.
Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology. 2013 Nov; 145(5):1035-1044.e5.
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013 Nov; 20(11):745-60.
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Honarvar M, Lobo J, Schneider C, Klein S, Smith GI, Loomba R, Ramji A, Hassanein T, Yoshida EM, Pang E, Curry MP, Afdhal NH
Methods and Validation of Velacur Determined Fat Fraction in patients with MASLD. WFUMB Ultrasound Open. 2024 Dec; 2(2).
Methods and Validation of Velacur Determined Fat Fraction in patients with MASLD.
Editorial. J Viral Hepat. 2014 Feb; 21(2):77.
Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014 Feb; 16(2):372.
Utilization of FibroScan in clinical practice.
Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014 Feb; 146(2):442-52.e1.
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
FibroScan in the Diagnosis of Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2013 Aug; 9(8):533-5.
FibroScan in the Diagnosis of Hepatitis C Virus Infection.
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17; 370(16):1483-93.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15; 370(20):1889-98.
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Donovan LM, Kress WL, Strnad LC, Sarwar A, Patwardhan V, Piatkowski G, Tapper EB, Afdhal NH
Low likelihood of intracranial hemorrhage in patients with cirrhosis and altered mental status. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):165-9.
Low likelihood of intracranial hemorrhage in patients with cirrhosis and altered mental status.
FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):27-36.
FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.
Reply: To PMID 24126097. Gastroenterology. 2014 Jul; 147(1):255-6.
Tapper EB, Krajewski K, Lai M, Challies T, Kane R, Afdhal N, Lau D
Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014 Nov; 2(4):276-80.
Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease.
Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther. 2014 Oct; 40(7):804-10.
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
Colagreco JP, Bailey DE, Fitzpatrick JJ, Musil CM, Afdhal NH, Lai M
Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C. J Viral Hepat. 2014 Oct; 21(10):727-33.
Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C.
Lin JC, Habersetzer F, Rodriguez-Torres M, Afdhal N, Lawitz EJ, Paulson MS, Zhu Y, Subramanian GM, McHutchison JG, Sulkowski M, Wyles DL, Schooley RT
Interferon ?-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J Infect Dis. 2014 Dec 15; 210(12):1881-5.
Interferon ?-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.
Contemporary assessment of hepatic fibrosis. Clin Liver Dis. 2015 Feb; 19(1):123-34.
Contemporary assessment of hepatic fibrosis.
Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015 Jan; 148(1):100-107.e1.
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Foster G, Afdhal NH, Karayiannis P, Thursz M
Welcome to the new, all electronic Journal of Viral Hepatitis. J Viral Hepat. 2015 Jan; 22(1):1.
Welcome to the new, all electronic Journal of Viral Hepatitis.
Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Curr Opin Gastroenterol. 2015 May; 31(3):192-8.
Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis.
Jiang ZG, Tsugawa Y, Tapper EB, Lai M, Afdhal N, Robson SC, Mukamal KJ
Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2015 Jul; 42(1):106-16.
Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States.
Sethi N, Tapper EB, Vong A, Sethi S, Rourke M, Afdhal NH
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. J Viral Hepat. 2015 Dec; 22(12):974-6.
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
Jain S, Rajasingham R, Noubary F, Coonahan E, Schoeplein R, Baden R, Curry M, Afdhal N, Kumar S, Pollock NR
Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples. PLoS One. 2015; 10(5):e0128118.
Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples.
Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015 Apr; 9(2):243-50.
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years.
Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, McHutchison JG
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):772-9.e1-3.
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study.
Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015 Jun; 61(6):1798-808.
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 2015 Jul; 62(1):25-30.
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 2015 Jul; 62(1):79-86.
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, Hunt SL, Marcellin P
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015 Aug; 63(2):337-45.
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gómez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D
Journal of gastroenterology and hepatology
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. J Gastroenterol Hepatol. 2015 Aug; 30(8):1301-8.
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol. 2015 Sep; 110(9):1298-304.
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci. 2016 Mar; 61(3):905-12.
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
Patwardhan VR, Jiang ZG, Risech-Neiman Y, Piatkowski G, Afdhal NH, Mukamal K, Curry MP, Tapper EB
Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis [corrected]. J Clin Gastroenterol. 2016 04; 50(4):345-50.
Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis [corrected].
Tapper EB, Catana AM, Sethi N, Mansuri D, Sethi S, Vong A, Afdhal NH
Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer. 2016 Mar 15; 122(6):852-8.
Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, Robson SC, Mukamal KJ
Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016 Mar; 43(6):734-43.
Aspirin use is associated with lower indices of liver fibrosis among adults in the United States.
Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, Gitlin N, Workowski K, Zhu Y, Yang JC, Pang PS, McHutchison JG, Muir AJ, Howell C, Kowdley K, Afdhal N, Reddy KR
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology. 2016 Feb; 63(2):437-44.
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.
Jiang ZG, Tapper EB, Connelly MA, Pimentel CF, Feldbrügge L, Kim M, Krawczyk S, Afdhal N, Robson SC, Herman MA, Otvos JD, Mukamal KJ, Lai M
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver Int. 2016 08; 36(8):1213-20.
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One. 2016; 11(2):e0147237.
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M
The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016 05; 111(5):677-84.
The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.
Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016 Apr; 63(4):1112-9.
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
Erratum: Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration-Controlled Transient Elastography. Am J Gastroenterol. 2016 Mar; 111(3):446.
Erratum: Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration-Controlled Transient Elastography.
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016 May; 61(5):1356-64.
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
Letter: would aspirin alleviate fibrosis in alcoholic liver disease? Authors' reply. Aliment Pharmacol Ther. 2016 07; 44(2):209-10.
Letter: would aspirin alleviate fibrosis in alcoholic liver disease? Authors' reply.
A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus Genotype 1. Gastroenterol Hepatol (N Y). 2014 Dec; 10(12):815-7.
A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus Genotype 1.
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology. 2016 09; 151(3):501-512.e1.
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Effect of Registries and Cohort Studies on HCV Treatment. Gastroenterology. 2016 09; 151(3):387-90.
Effect of Registries and Cohort Studies on HCV Treatment.
Proteomics and Biomarkers for Hepatocellular Cancer
Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease
Antiviral Therapy in African Americans with HCV
Determinants of Liver Injury in Chronic Hepatitis C Virus Infection
PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016 12; 64(6):1893-1899.
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017 01; 24(1):22-27.
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
Welzel TM, Reddy KR, Flamm SL, Denning J, Lin M, Hyland R, Pang PS, McHutchison JG, Charlton M, Everson GT, Zeuzem S, Afdhal N
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD, Mo H, Gane EJ
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017 04; 66(4):703-710.
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
Suresh M, Korolowicz KE, Balarezo M, Iyer RP, Padmanabhan S, Cleary D, Gimi R, Sheri A, Yon C, Kallakury BV, Tucker RD, Afdhal N, Menne S
Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017; 12(1):e0169631.
Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks.
Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, McHutchison JG, Younossi Z, Marcellin P, Patel K
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clin Gastroenterol Hepatol. 2017 Jul; 15(7):1087-1094.e2.
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.
Current treatment options in gastroenterology
Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor). Curr Treat Options Gastroenterol. 2002 Apr; 5(2):87-94.
Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor).
Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem. 2004 Aug; 50(8):1299-300.
Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?
Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology. 2006 Apr; 43(4):788-95.
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Li H, Sferruzza A, Qu KZ, Afdhal NH, Lai M, Radcliff JS, Bender RA
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Utility of four tumor markers, alone and in combination, for detection of hepatocellular carcinoma: AFP, AFP-L3, DCP, and Cystatin. J Clin Oncol. 2008 May 20; 26(15_suppl):4585.
Utility of four tumor markers, alone and in combination, for detection of hepatocellular carcinoma: AFP, AFP-L3, DCP, and Cystatin.
Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, Curry MP, Afdhal NH
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2017 05; 101(5):987-995.
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
Offner GD, Nunes DP, Keates AC, Afdhal NH, Troxler RF
Biochemical and biophysical research communications
The amino-terminal sequence of MUC5B contains conserved multifunctional D domains: implications for tissue-specific mucin functions. Biochem Biophys Res Commun. 1998 Oct 09; 251(1):350-5.
The amino-terminal sequence of MUC5B contains conserved multifunctional D domains: implications for tissue-specific mucin functions.
Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Jones M, Cunningham ME, Wing P, DeSilva S, Challa R, Sheri A, Padmanabhan S, Iyer RP, Korba BE, Afdhal N, Foster GR
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 09; 89(9):1620-1628.
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.
Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R
Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008 Jun; 48(6):1000-7.
Thrombocytopenia associated with chronic liver disease.
Cardenas A, Lowe R, Oh S, Bodkin S, Kenney T, Lamorte WW, Afdhal NH
Scandinavian journal of gastroenterology
Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis. Scand J Gastroenterol. 2008 Mar; 43(3):328-33.
Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis.
Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2009 Apr; 24(4):564-8.
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
Noninvasive Markers of Liver Fibrosis. Gastroenterol Hepatol (N Y). 2006 Jun; 2(6):413-415.
Good cholesterol, bad cholesterol: role of oxysterols in biliary tract diseases. Gastroenterology. 2001 Jul; 121(1):216-8.
Good cholesterol, bad cholesterol: role of oxysterols in biliary tract diseases.
Symptomatic focal nodular hyperplasia during pregnancy: a case report. Ann Hepatol. 2004 Jan-Mar; 3(1):35-7.
Symptomatic focal nodular hyperplasia during pregnancy: a case report.
Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005 Mar 24; 19(6):585-92.
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.
Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis. 2005 Aug; 9(3):439-51, vii.
Use of growth factors with antiviral therapy for chronic hepatitis C.
Afdhal NH, Keaveny AP, Cohen SB, Nunes DP, Maldonado N, O'Brien M, Stone PJ
Urinary assays for desmosine and hydroxylysylpyridinoline in the detection of cirrhosis. J Hepatol. 1997 Dec; 27(6):993-1002.
Urinary assays for desmosine and hydroxylysylpyridinoline in the detection of cirrhosis.
Crohn's and stones. Am J Gastroenterol. 1999 May; 94(5):1130-2.
Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep. 2001 Feb; 3(1):12-8.
Hepatic fibrosis: are any of the serum markers useful?
Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004 Jun; 99(6):1160-74.
Evaluation of liver fibrosis: a concise review.
Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, Afdhal N, Koziel MJ, Exley MA
Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol. 2004 Aug 01; 173(3):2159-66.
Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells.
Antiviral therapy for treatment naïve patients with hepatitis C virus. Gastroenterol Clin North Am. 2004 Sep; 33(3):497-511, viii.
Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006 Mar; 130(3):632-8.
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
Nature clinical practice. Gastroenterology & hepatology
Can serum markers be used to reliably detect liver fibrosis? Nat Clin Pract Gastroenterol Hepatol. 2005 Mar; 2(3):132-3.
Can serum markers be used to reliably detect liver fibrosis?
Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007 Jan; 45(1):80-7.
Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
Mac Mathuna P, Siegenberg D, Gibbons D, Gorin D, O'Brien M, Afdhal NA, Chuttani R
The acute and long-term effect of balloon sphincteroplasty on papillary structure in pigs. Gastrointest Endosc. 1996 Dec; 44(6):650-5.
The acute and long-term effect of balloon sphincteroplasty on papillary structure in pigs.
Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A, Magder LS, Afdhal NH, Strickland GT
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004 Nov; 36(11):752-9.
Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results.
Stefan AM, Coulter S, Gray B, LaMorte W, Nikelaeson S, Edge AS, Afdhal NH
Xenogeneic transplantation of porcine hepatocytes into the CCl4 cirrhotic rat model. Cell Transplant. 1999 Nov-Dec; 8(6):649-59.
Xenogeneic transplantation of porcine hepatocytes into the CCl4 cirrhotic rat model.
Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation. 2017 05; 101(5):933-937.
Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C.
Therapy of Digestive Disorders Wolfe MM, Ed.
Bacterial, Fungal and Granulomatous Diseases of the Liver. Therapy of Digestive Disorders Wolfe MM, Ed. 1999; 315-22.
Bacterial, Fungal and Granulomatous Diseases of the Liver
John B. Gross, Paul Kwo, Nezam Afdhal, RENEW Investigator Group
Interim Results in the RENEW Trial: A Dose Comparison Study of High-Dose PegInterferon Alfa-2B and Ribavirin for Interferon/Ribavirin Non-Responders with Chronic Hepatitis C. Hepatology. 2002; 36(4):359A.
Interim Results in the RENEW Trial: A Dose Comparison Study of High-Dose PegInterferon Alfa-2B and Ribavirin for Interferon/Ribavirin Non-Responders with Chronic Hepatitis C
Changqing Yang, Hikaru Sugimoto, Sudhakar Akulppalli, Mauricio Giraldo, Nezam Afdhal, Michael Zeisberg, Raghu Kalluri
Effects of BMP-7 on Liver Regeneration after Partial Hepatectomy in Mice. Gastroenterology. 2003; 124(4):A-755.
Effects of BMP-7 on Liver Regeneration after Partial Hepatectomy in Mice
Robert Brown, Ira Jacobson, Nezam Afdhal, Ray Rubin, James Spivey, Frederic Regenstein, David Bernstein, Clifford Brass, Bradley Freilich
Racial/Ethnic Differences in Hematologic Toxicity of Pegylated Interferon and Ribavirin Therapy: Analysis of the Win-R Trial. Hepatology. 2002; 36(4):292A.
Racial/Ethnic Differences in Hematologic Toxicity of Pegylated Interferon and Ribavirin Therapy: Analysis of the Win-R Trial
Acute Cholangitis, Up to Date in Medicine, Gastroenterology Series
Acute Cholangitis, Up to Date in Medicine, Gastroenterology Series. 1997.
Afdhal NH, Long A, Tobbia I, Cullen A, O'Donoghue DP
Immunohistochemical Cal9-9 in primary colonic polyps and polyps synchronous with colorectal cancer. Gut. 1987 May; 28(5):594-600.
Immunohistochemical Cal9-9 in primary colonic polyps and polyps synchronous with colorectal cancer.
Malik R, Farnan R, Lai M, Freitag H, Schuppan D, Afdhal NH
Comparison of Fibroscan, APRI, AST/ALT and Clinical Signs as non invasive predictors of Cirrhosis. Hepatology. 2007; 46:428A.
Comparison of Fibroscan, APRI, AST/ALT and Clinical Signs as non invasive predictors of Cirrhosis
McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-Adhami M, Morris ML, Lekstrom-Himes JA, Efler SM, Davis HL
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 2007 Nov; 46(5):1341-9.
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
A recombinant bovine gallbladder mucin polypeptide binds biliary lipids and accelerates cholesterol crystal appearance time. Gastroenterology. 1999 Apr; 116(4):936-42.
A recombinant bovine gallbladder mucin polypeptide binds biliary lipids and accelerates cholesterol crystal appearance time.
O'Brien S, Keogan M, Patchett S, McCormick PA, Afdhal N, Hegarty JE
Postprandial changes in portal haemodynamics in patients with cirrhosis. Gut. 1992 Mar; 33(3):364-7.
Postprandial changes in portal haemodynamics in patients with cirrhosis.
Keates AC, Nunes DP, Afdhal NH, Troxler RF, Offner GD
Molecular cloning of a major human gall bladder mucin: complete C-terminal sequence and genomic organization of MUC5B. Biochem J. 1997 May 15; 324 ( Pt 1):295-303.
Molecular cloning of a major human gall bladder mucin: complete C-terminal sequence and genomic organization of MUC5B.
Noninvasive assessment of liver fibrosis. Clin Liver Dis. 2005 Nov; 9(4):667-83, vii.
Noninvasive assessment of liver fibrosis.
Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP
Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec; 30(12):1704-7.
Clot lysis by gastric juice: an in vitro study.
Kornek M, Popov Y, Libermann TA, Afdhal NH, Schuppan D
Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology. 2011 Jan; 53(1):230-42.
Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells.
Afdhal NH, Offner GD, Murray FE, Troxler RF, Smith BF
Isolation and characterization of peptides from the protein core of bovine gallbladder mucin. Gastroenterology. 1990 Jun; 98(6):1633-41.
Isolation and characterization of peptides from the protein core of bovine gallbladder mucin.
Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology. 2006 Apr; 43(4):771-9.
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis.
Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology. 2006 Jul; 131(1):210-22.
Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice.
Afdhal NH, Cao X, Bansil R, Hong Z, Thompson C, Brown B, Wolf D
Interaction of mucin with cholesterol enriched vesicles: role of mucin structural domains. Biomacromolecules. 2004 Mar-Apr; 5(2):269-75.
Interaction of mucin with cholesterol enriched vesicles: role of mucin structural domains.
Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallée M, Dev A, Smith-Riggs M, McHutchison JG
Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):242-7.
Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.
EUS-guided liver biopsy: a procedure looking for an indication. Gastrointest Endosc. 2009 Mar; 69(3 Pt 1):543-5.
EUS-guided liver biopsy: a procedure looking for an indication.
Benhamou Y, Afdhal NH, Nelson DR, Shiffman ML, Halliman DG, Heise J, Chun E, Pockros PJ
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Hepatology. 2009 Sep; 50(3):717-26.
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.
Clinical utility of interleukin-28B testing in patients with genotype 1. Hepatology. 2012 Jul; 56(1):367-72.
Clinical utility of interleukin-28B testing in patients with genotype 1.
Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, Higgins Y, Moore RD, Afdhal N, Torbenson M, Sulkowski M, Thomas DL
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009 Apr 01; 48(7):963-72.
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.
Xiao-Jian Zhou, Nezam Afdhal, Eliot Godofsky, Jules Dienstag; Vinod Rustgi, Lawton Schick. Lael Duncan, Barbara Fielman Constance, George Chao, Nathaniel A. Brown
Pharmacokinetics and Pharmacodynamics of Valopictabine (nm283), a new nucleoside Hcv polymerase inhibitor: results from a phase I/ii dose-escalation trial in patients with Hcv-1 infection. Gastroenterology. 2005; 128(4):a-700.
Pharmacokinetics and Pharmacodynamics of Valopictabine (nm283), a new nucleoside Hcv polymerase inhibitor: results from a phase I/ii dose-escalation trial in patients with Hcv-1 infection
Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010 Dec; 52(6):1888-96.
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.
Pritchett S, Cardenas A, Manning D, Curry M, Afdhal NH
The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific. J Viral Hepat. 2011 Apr; 18(4):e75-80.
The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific.
John McHutchinson, Duke Univeristy, Durham, NC; Bruce Bacon, St. Louis University Hospital, St. Louis, MO; Stuart C. Gordon, Henry Ford Hospital, Detroit, MI; Eric Lawitz, Alamo Medical Research, San Antonio, TX; Michell Shiffman, Medical College of Virginia, Richmond, VA; Nezam H. Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Ira Jacobson, Cornell University, New York, NY; Andrew Muir, Duke Univeristy, Duram, NC; Susan Elfer, Coley Pharmaceutical Group, Ottawa, Canada; Mohammed Al-Adhami, Coley Pharmaceuticals Group, Wellesley, MA; Heather Davis, Coley Pharmaceutical Group, Ottawa, Canada; Tess Schmalbach, Coley Pharmaceutical Group, Wellesley, MA
Relationship of HCV RNA responses to CPG 10101, A TLR9 Agonist: Pharmacodynamics and patient characteristics. Hepatology. 2005; 42(4):75A.
Relationship of HCV RNA responses to CPG 10101, A TLR9 Agonist: Pharmacodynamics and patient characteristics
Interaction of biliary cholesterol with mucin gels. Gastroenterology. 1994; (106):925A.
Interaction of biliary cholesterol with mucin gels
Tung BY, Afdhal NH, Nunes DP, Thummel KE, Kharasch ED, Croghan AM, Cox PP, Lin M, Kowdley KV
The effect of iron depletion on serum markers of lipid peroxidation and fibrosis in hepatitis C. Hepatology. 1998; (28):568A.
The effect of iron depletion on serum markers of lipid peroxidation and fibrosis in hepatitis C
Maribel Rodiguez-Torres, Eric Lawitz, Eliot Godofsky, Nezam Afdhal, George Chao, Barbara Fielman Constance, Steven Knox, Nathaniel A. Brown
Valopitabine (nm283) alone and in combination with peg-interferon in patients with genotype 1 chronic hepatitis C: Preliminary results from an ongoing phase II, multicenter study. Gastroenterology. 2005; 128(4):p-90.
Valopitabine (nm283) alone and in combination with peg-interferon in patients with genotype 1 chronic hepatitis C: Preliminary results from an ongoing phase II, multicenter study
Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R
Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 2003 Dec 01; 63(23):8312-7.
Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment.
Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, Lee Y, Milligan S, Tsai N, Younossi Z, Afdhal NH
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017 09; 46(5):540-548.
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Neurologic Manifestations of Hepatitis C Virus Infection. Clin Liver Dis. 2017 08; 21(3):535-542.
Neurologic Manifestations of Hepatitis C Virus Infection.
Koziel MJ, Dudley D, Afdhal N, Choo QL, Houghton M, Ralston R, Walker BD
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol. 1993 Dec; 67(12):7522-32.
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV.
Gastroenterologie clinique et biologique
Diagnosis of liver fibrosis in 2008 and beyond. Gastroenterol Clin Biol. 2008 Sep; 32(6 Suppl 1):88-90.
Diagnosis of liver fibrosis in 2008 and beyond.
Health care quality measurement in the care of patients with cirrhosis. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):649-50.
Health care quality measurement in the care of patients with cirrhosis.
Afdhal NH, Niu N, Gantz D, Small DM, Smith BF
Bovine gallbladder mucin accelerates cholesterol monohydrate crystal growth in model bile. Gastroenterology. 1993 May; 104(5):1515-23.
Bovine gallbladder mucin accelerates cholesterol monohydrate crystal growth in model bile.
Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, El Gohary LA, Ramy AH, Madwar MA, Rasenack J, Afdhal NH
Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006 May; 43(5):923-31.
Duration of peginterferon therapy in acute hepatitis C: a randomized trial.
Cao X, Bansil R, Bhaskar KR, Turner BS, LaMont JT, Niu N, Afdhal NH
pH-dependent conformational change of gastric mucin leads to sol-gel transition. Biophys J. 1999 Mar; 76(3):1250-8.
pH-dependent conformational change of gastric mucin leads to sol-gel transition.
Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009 Dec; 50(6):1719-26.
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011 Feb; 140(2):469-77.
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
Howell CD, Gorden A, Ryan KA, Thompson AJ, Ibrahim C, Fried M, Afdhal NH, McHutchison JG, Shianna KV, Goldstein DB, Shuldiner AR, Mitchell BD
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol. 2012 Mar; 56(3):557-63.
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012 Aug 23; 367(8):716-24.
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Alex S Befer, Saint Louis University, St Louis, MO; Jorge A Marrero, Univeristy of Michigan, Ann Arbor, MI; Ravi S Chari, Vanderbilt Univeristy, Nashville, TN; Lewis Roberts, Mayo Clinic, Rochester, MN; Nezam Afdhal, Harvard University Beth Israel Deaconess Hopsital, Boston, MA; David van Thiel, Loyola Univeristy, Chicago, IL; Adrian M Di Bisceglie, Saint Louis Univeristy, St Louis, MO
The Epidemiology and survival of patients with Hepatocellular Carcinoma in the United States - A prelininary report from the liver cancer network. Hepatology. 2004; 40(4):216A.
The Epidemiology and survival of patients with Hepatocellular Carcinoma in the United States - A prelininary report from the liver cancer network
Malik R, Lai M, Sadiq A, Farnan R, Mehta S, Nasser I, Challies T, Schuppan D, Afdhal N
Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol. 2010 Sep; 25(9):1562-8.
Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis.
Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology. 2011 Jan; 53(1):336-45.
Hepatitis C pharmacogenetics: state of the art in 2010.
Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? JAMA. 2012 Aug 08; 308(6):608-16.
Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?
Nezam H. Afdhal, Bradley Freilich, Martin Black, Robert Levine, Clifford Brass
Comparison of Therapy with Peg-Intron 0.5mcg/kg Versus Colchicine 0.6mg BID in 250 Patients with Cirrhosis and HCV; Interim Data from Copilot. Hepatology. 2002; 36(4):312A.
Comparison of Therapy with Peg-Intron 0.5mcg/kg Versus Colchicine 0.6mg BID in 250 Patients with Cirrhosis and HCV; Interim Data from Copilot
Valerie M. Byrnes, Honghu Shi, Shigeru Kiryu, Neil M. Rofsky, Nezam H. Afdhal
The Fate of Arterial Enhancing Nodules on MRI in the Cirrhotic Liver. Gastroenterology. 2004; 126(4):A-679.
Protecting New Jersey's Public Health; What healthcare professionals must know about hepatitis C
Protecting New Jersey's Public Health; What healthcare professionals must know about hepatitis C. 1999.
Calcium preferentially accelerates gallbladder mucin induced cholesterol monohydrate crystal nucleation rather than crystal growth in model bile. Gastroenterology. 1991; (100):781.
Calcium preferentially accelerates gallbladder mucin induced cholesterol monohydrate crystal nucleation rather than crystal growth in model bile
Helen H. Wang, Nezam H. Afdhal, David Q.-H. Wang
Targeted Disruption of Mucin Gene 1 (Muc1) Decreases Susceptibility to Cholesterol (Ch) Gallstone Formation in Mice. Gastroenterology. 2003; 124(4):A-698.
Targeted Disruption of Mucin Gene 1 (Muc1) Decreases Susceptibility to Cholesterol (Ch) Gallstone Formation in Mice
Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M
Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011 Apr; 45(4):355-60.
Circulating microRNAs as biomarkers for hepatocellular carcinoma.
Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559.
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Strickland GT, Tanamly MD, Tadros F, Labeeb S, Makld H, Nessim D, Mikhail N, Magder LS, Afdhal NH, Medhat A, Abdel-Hamid M
Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig Liver Dis. 2005 Jul; 37(7):542-3.
Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C.
Exceeding the limits of liver histology markers. J Hepatol. 2009 Jan; 50(1):36-41.
Exceeding the limits of liver histology markers.
Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH
Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009 Jun; 7(6):696-701.
Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States.
Wang HH, Portincasa P, Afdhal NH, Wang DQ
Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am. 2010 Jun; 39(2):185-207, vii-viii.
Lith genes and genetic analysis of cholesterol gallstone formation.
Cao X, Bansil R, Gantz D, Moore EW, Niu N, Afdhal NH
Diffusion behavior of lipid vesicles in entangled polymer solutions. Biophys J. 1997 Oct; 73(4):1932-9.
Diffusion behavior of lipid vesicles in entangled polymer solutions.
McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Piratvisuth T, Marcellin P, Fried MW
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013 Apr; 57(4):1325-32.
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.
Nezam H Afdhal, Angela Klopfer, Linda Tang, Zobair Younossi
Hemoglobin Increase is Independently Associated with Increased Health-Related Quality of Life (HRQL)in Anemic Interferon/Ribavirin (IFN/RBV)-Treated Hepatitis C Virus (HCV)-Infected Patients Treated with Epoetin Alfa. Hepatology. 2003; 38(4):312A.
Hemoglobin Increase is Independently Associated with Increased Health-Related Quality of Life (HRQL)in Anemic Interferon/Ribavirin (IFN/RBV)-Treated Hepatitis C Virus (HCV)-Infected Patients Treated with Epoetin Alfa
Helen H. Wang, Nezam H. Afdhal, David Q.H. Wang
Overexpression of Estrogen Receptor Alfa (ER-Alfa)Inhibits the Negative Feedback Regulation of Cholesterol (Ch) Biosynthesis and Increases Newly Synthesized Ch Leading to Biliary Ch Hypersecretion. Gastroenterology. 2004; 126(4):A-673.
Overexpression of Estrogen Receptor Alfa (ER-Alfa)Inhibits the Negative Feedback Regulation of Cholesterol (Ch) Biosynthesis and Increases Newly Synthesized Ch Leading to Biliary Ch Hypersecretion
Afdhal NH, McHutchison JG, Shiffman ML, Rodrigues Torres, M, Dusheioko GM, Sigal S, White S, Blackman N, Cambell F, Dickens T.
Eltrombopag raises platelet count in 2 weeks in patients with HCv and significant thrombocytopenia. Hepatology. 2007; 46:252A.
Eltrombopag raises platelet count in 2 weeks in patients with HCv and significant thrombocytopenia
Pathogenesis of Cholesterol Gallstones. Viewpoints on Digestive Disease. 1990; 22:13-18.
Principles and Practices of Gastroenterology and Hepatology, Gitnick G, Ed.
Pathogenesis of Gallstones. Principles and Practices of Gastroenterology and Hepatology, Gitnick G, Ed. 1994; 561-571.
Malik R, Lai M, BhaskarIN, Curry M, Schuppan D, Afdhal NH
Identification of Biomakers that measure disease activity in patients with nonalcoholic fatty liver disease. Hepatology. 2008; 48:s355.
Identification of Biomakers that measure disease activity in patients with nonalcoholic fatty liver disease
Future therapies for hepatitis C. Current Hepatitis Reports. 2006; 5:121-128.
Paul J. Pockros, Lennox Jeffers, Nezam Afdhal, Zachary D. Goodman, David Nelson, Robert Gish, Rajender Reddy, Robert Reindollar, Maribel Rodiguez-Torres, Sima FarisYoung, Sara Sullivan, Lawrence M. Blatt
Final Result of a double-blind, Placebo-controlled trial of the antibibrotic efficacy of INF Gamma-1b in chronic hepatitis C patients with advanced fibrosis or cirrosis. Gastroenterology. 2005; 128(4):p-175.
Final Result of a double-blind, Placebo-controlled trial of the antibibrotic efficacy of INF Gamma-1b in chronic hepatitis C patients with advanced fibrosis or cirrosis
John Gross, Stephanie Johnson, Mayo Clinic, Rochester, MN; Paul Kwo, Indiana U. School of Medicine, Indianapolis, IN; Nezam H. Afdhal, beth Israel Deaconess Medical Center, Boston, MA; Stven Flamm, Northwestern U. Department of Medicine, Chicago, IL; Terry Therneau, The RENEW Investigators, Mayo Clinic, Rochester, MN
Double-Dose PegInterferon Alfa-2B with wieghtbased ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: Final results of "RENEW". Hepatology. 2005; vol. 42(No. 4):63A.
Double-Dose PegInterferon Alfa-2B with wieghtbased ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: Final results of "RENEW"
Duzendorfer D, Lee V, Chipkin S, Afdhal NH, Karasik M
HIDA scintigraphy as a test for small intestinal transit: Effect of acute hyperglycemia. American Journal of Gastroenterology. 1995; (90):1631.
HIDA scintigraphy as a test for small intestinal transit: Effect of acute hyperglycemia
Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP
Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci. 1991 Apr; 36(4):449-53.
Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo.
Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice. J Lipid Res. 2006 Apr; 47(4):778-86.
Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice.
Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol. 2006 Oct; 4(10):1214-1220.
Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group.
Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am. 2004 Mar; 33(1 Suppl):S25-35.
Role of epoetin alfa in maintaining ribavirin dose.
Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004 May; 126(5):1302-11.
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Byrnes V, Afdhal N, Challies T, Greenstein PE
Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis. Ann Hepatol. 2006 Jan-Mar; 5(1):56-9.
Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med. 2009 Apr 30; 360(18):1902-6.
Clinical decisions. Management of incidental hepatitis C virus infection.
Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007 Oct; 46(4):971-81.
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Stiffness and impedance: the new liver biomarkers. Clin Gastroenterol Hepatol. 2007 Oct; 5(10):1144-6.
Stiffness and impedance: the new liver biomarkers.
Ultrasound-based hepatic elastography: origins, limitations, and applications. J Clin Gastroenterol. 2010 Oct; 44(9):637-45.
Ultrasound-based hepatic elastography: origins, limitations, and applications.
Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW
Drug metabolism and disposition: the biological fate of chemicals
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos. 2011 Dec; 39(12):2182-90.
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
Mehta SH, Kirk GD, Astemborski J, Sulkowski MS, Afdhal NH, Thomas DL
Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther. 2012; 17(5):813-21.
Stability of liver fibrosis among HCV-infected injection drug users.
Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012 Jul 18; 308(3):274-82.
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
Epidemiology of and risk factors for gallstones
Epidemiology of and risk factors for gallstones. 1998.
Biliary Tract Disease. Primary Care Medicine Noble J, Ed. 1996; 605-13.
Nonalcoholic steatohepatitis (NASH) Editors: Bataller R, Caballeria J.
Nonivasive diagnosis of NASH. Nonalcoholic steatohepatitis (NASH) Editors: Bataller R, Caballeria J. 2007; 111-120.
Helen H Wang, Nezam H Afdhal, David Q Wang
Increased Fecal Neutral Sterol and Bile Acid Excretion Confers Resistance to Diet-Induced Cholesterol (CH) Cholelithiasis in Gallstone-Resistant AKR Mice. Hepatology. 2002; 36(4):460A.
Increased Fecal Neutral Sterol and Bile Acid Excretion Confers Resistance to Diet-Induced Cholesterol (CH) Cholelithiasis in Gallstone-Resistant AKR Mice
Christopher O'brien, University of Miami, Miami, FL; Eliot Godofsky, Bach & Godofsky, Brandenton, FL; Maribel Rodriguez-Torres, Fundacion de Investigacion de diego, Sanurce, Puerto Rico; Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; S.C. Pappas, St. Luke's Episcopal Hospital
Randomized trial of valopicitabine (NM283), alone or with Peg-Interferon, VS. Retreatment with peg-interferon plus ribavirin (Peginf/rbv) in hepatitis C patients with pervious non-response to pegifn/rbv: first interi, results. Hepatology. 2005; vol. 42(no. 4):69A.
Randomized trial of valopicitabine (NM283), alone or with Peg-Interferon, VS. Retreatment with peg-interferon plus ribavirin (Peginf/rbv) in hepatitis C patients with pervious non-response to pegifn/rbv: first interi, results
Eric J. Lawitz, Stephen A. Harrison, Norma S. Cantu, Shailesh C. Kadakia, K.P. Ganeshappa, Frank Adams, Mitchell Davis, Richard Sperling, Naoky Tsai, Andrei Gasic, Tarum Kothari, James Cox, Barry Sanders, Bruce Silverman, Elias Ghandour, Jeffrey Medoff, Vajravel Prasad, Nezam Afdhal, Mark Mailliard, Michael Curry, Alamo Study Group
The Effect of Amantadine on Sustained Virologic Response when Added to Pegylated Interferon Alfa 2b + Weight Based Ribavirin in Previous Nonresponders and Relapsers. Gastroenterology. 2004; 126(4):A-697.
The Effect of Amantadine on Sustained Virologic Response when Added to Pegylated Interferon Alfa 2b + Weight Based Ribavirin in Previous Nonresponders and Relapsers
Characterization of bovine gallbladder mucin. Amino acid sequences of tryptic peptides from the glycosylated domain of the protein core. Gastroenterology. 1990 Nov; 99(5):1493-501.
Characterization of bovine gallbladder mucin. Amino acid sequences of tryptic peptides from the glycosylated domain of the protein core.
Byrnes V, Shi H, Kiryu S, Rofsky NM, Afdhal NH
The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver. Am J Gastroenterol. 2007 Aug; 102(8):1654-9.
The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver.
Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007 Aug; 46(2):324-9.
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.
Keatinge AM, Johnson AH, Collins PB, Afdhal N, Lynch D, Lavin JN
Vitamin B1, B2, B6 and C status in the elderly. Ir Med J. 1983 Dec; 76(12):488-90.
Vitamin B1, B2, B6 and C status in the elderly.
Afdhal NH, Smith J, Heffernan S, Doyle JS, Gaffney E
Acute small bowel obstruction secondary to endometriosis: two case reports and a review of the literature. Ir Med J. 1984 May; 77(5):141-3.
Acute small bowel obstruction secondary to endometriosis: two case reports and a review of the literature.
Diagnosis and quantitation of fibrosis. Gastroenterology. 2008 May; 134(6):1670-81.
Guo W, Kurze V, Huber T, Afdhal NH, Beyer K, Hamilton JA
A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systems. Biophys J. 2002 Sep; 83(3):1465-78.
A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systems.
American journal of physiology. Gastrointestinal and liver physiology
Lack of the intestinal Muc1 mucin impairs cholesterol uptake and absorption but not fatty acid uptake in Muc1-/- mice. Am J Physiol Gastrointest Liver Physiol. 2004 Sep; 287(3):G547-54.
Lack of the intestinal Muc1 mucin impairs cholesterol uptake and absorption but not fatty acid uptake in Muc1-/- mice.
Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones. Gastroenterology. 2004 Jul; 127(1):239-49.
Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones.
Jiang ZG, Sandhu B, Feldbrügge L, Yee EU, Csizmadia E, Mitsuhashi S, Huang J, Afdhal NH, Robson SC, Lai M
Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018 07; 16(7):1170-1172.
Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease.
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011 Sep 15; 365(11):1014-24.
Response-guided telaprevir combination treatment for hepatitis C virus infection.
Gish RG, Afdhal NH, Dieterich DT, Reddy KR
Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol. 2005 Apr; 3(4):311-8.
Management of hepatitis C virus in special populations: patient and treatment considerations.
Consultations in Gastroenterology Snape WJ, Ed.
Acalculous cholecystitis. Consultations in Gastroenterology Snape WJ, Ed. 1996; 853-7.
Stuart C Gordon, Bruce R Bacon, Ira M Jacobson, Mitchell L Shiffman, Nezam H Afdhal, Rosie Z Yu, John G McHutchison, Jesse Kwoh
Treatment of Chronic Hepatitis C with ISIS 14803, An Antisense Inhibitor of HCV, Given for 12 Weeks. Hepatology. 2003; 38(4):306-7A.
Treatment of Chronic Hepatitis C with ISIS 14803, An Antisense Inhibitor of HCV, Given for 12 Weeks
Zhenning Hong, Rama Bansil, Nezam H. Afdhal, K. Ramakrishnan Bhaskar, Bradley S. Turner
Biophysical Journal (Poster presentation at the 45th annual meeting of the Biophysical Society, Boston, MA Feb. 17-21, 2001)
Formation and growth of cholesterol crystals in polymer solutions from model bile. Biophysical Journal (Poster presentation at the 45th annual meeting of the Biophysical Society, Boston, MA Feb. 17-21, 2001). 2001; 2(80):546a.
Formation and growth of cholesterol crystals in polymer solutions from model bile
Pancreatic and Hepatobiliary Infections in AIDS Patients. Gastrointestinal Infections LaMont JT, Ed. 1997; 361-97.
Pancreatic and Hepatobiliary Infections in AIDS Patients
Approach to the patient with incidental gallstones
Approach to the patient with incidental gallstones. 1999.
McCormick PA, Ramsay N, Afdhal N, Shattuck AG, Hillary IB, Tubridy D, O'Donoghue DP
Serological markers of hepatitis B virus (HBV) infection in alcoholics and hospital controls. Ir J Med Sci. 1988 Mar; 157(3):77-8.
Serological markers of hepatitis B virus (HBV) infection in alcoholics and hospital controls.
Bernard Chasan, Zhenning Hong, Rama Bansil, Bradley Turner, K. Ramakrishnan Bhaskar, Nezam Afdhal
Bulletin of the American Physical Society March poster presentation at the annual meeting of the American Physical Society, Seattle, WA
Atomic force microscopy of gastric mucin. Bulletin of the American Physical Society March poster presentation at the annual meeting of the American Physical Society, Seattle, WA. 2001; (46(1)):829.
Atomic force microscopy of gastric mucin
Yury Popov, BIDMC, Harvard Medical School, Boston, MA; Sebastian Meuller, Brad Turner, BIDMC, Harvard Medical School, Boston, MA; N. Zinkin, BIDMC, Boston, MA; I. Nasser, H. Masuzaki, BIDMC, Harvard Medical School, Boston, MA; J. Vriereck, Dept. or Neurology and Biophysics, Boston Medical Center, Boston, MA; J. Hamilton, Dept. or Neurology and Biophysics Boston Medical Center, Boston, MA; J. Flier, Nezam Afdhal, Detlef Schuppan, BIDMC, Harvard Medical School, Boston, MA
Mice overexpressing 11B-hydroxysteriod-dehydrogenase (HSD-1) in adipose tisure develop NASH and progressive pericentral fibrosis on a high fat diet. Hepatology. 2005; 42(4):168A.
Mice overexpressing 11B-hydroxysteriod-dehydrogenase (HSD-1) in adipose tisure develop NASH and progressive pericentral fibrosis on a high fat diet
Hari S Conjeevaram, David E Kleiner, Nezam Afdhal, Robert S Brown, Michael W Fried, Charles D Howell, Lennox J Jeffers, Nora Terrault, Thelma E Wiley, Chris Cherry, Steve Belle, Jay H Hoofnagle
Race, Insulin Resistance, Visceral Adiposity and Hepatic Steatosis in Genotype 1 Patients with Chronic Hepatitis C. Hepatology. 2003; 38(4):347A.
Race, Insulin Resistance, Visceral Adiposity and Hepatic Steatosis in Genotype 1 Patients with Chronic Hepatitis C
Identification of a 130-kilodalton human biliary concanavalin A binding protein as aminopeptidase N. Gastroenterology. 1994 Mar; 106(3):755-62.
Identification of a 130-kilodalton human biliary concanavalin A binding protein as aminopeptidase N.
Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y). 2012 Sep; 8(9):605-7.
Fibroscan (transient elastography) for the measurement of liver fibrosis.
AGA GTP Project 2003, Viral Hepatitis Section
AGA GTP Project 2003, Viral Hepatitis Section. 2003.
Nezam H Afdhal, Christopher B O'Brien, Scott C Oshana, Lisa M Dunkle
Potent Anti-HBV Activity of ACH-126,443 Correlated with 14-Day Pharmacokinetics and Safety: Predictions for Activity Against YMDD Mutant Strains. Hepatology. 2002; 36(4):372A.
Potent Anti-HBV Activity of ACH-126,443 Correlated with 14-Day Pharmacokinetics and Safety: Predictions for Activity Against YMDD Mutant Strains
Diseases of the Gallbladder and Biliary Tract N.H. Afdhal, Ed.
Diseases of the Gallbladder and Biliary Tract. Diseases of the Gallbladder and Biliary Tract N.H. Afdhal, Ed. 2000.
Diseases of the Gallbladder and Biliary Tract
Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindollar R, Rodriguez-Torres M, Sullivan S, Blatt LM, Faris-Young S
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology. 2007 Mar; 45(3):569-78.
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis.
Cholesterol crystal nucleation: a decade-long search for the missing link in gallstone pathogenesis. Hepatology. 1990 Apr; 11(4):699-702.
Cholesterol crystal nucleation: a decade-long search for the missing link in gallstone pathogenesis.
Celli JP, Turner BS, Afdhal NH, Ewoldt RH, McKinley GH, Bansil R, Erramilli S
Rheology of gastric mucin exhibits a pH-dependent sol-gel transition. Biomacromolecules. 2007 May; 8(5):1580-6.
Rheology of gastric mucin exhibits a pH-dependent sol-gel transition.
Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches. Aliment Pharmacol Ther. 2007 Nov; 26 Suppl 1:1-4.
Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches.
Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection. Aliment Pharmacol Ther. 2007 Nov; 26 Suppl 1:29-39.
Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection.
Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL, Naggie S, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, King JW, Kwo PY, Shianna KV, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Goldstein DB, McHutchison JG, Muir AJ
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012 Feb; 56(2):313-9.
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, Afdhal N, Rosen HR
Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology. 2011 Nov; 54(5):1559-69.
Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.
Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010 Oct; 139(4):1181-9.
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH, Hudson ML, Howell CD, Talloen W, Bollekens J, De Wit M, Scholliers A, Fried MW
Quantitation of pretreatment serum interferon-?-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011 Jan; 53(1):14-22.
Quantitation of pretreatment serum interferon-?-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.
Evaluation of liver lesions. Clin Liver Dis. 2012 May; 16(2):271-83.
Afdhal, NH, Manns MP, Lennox JJ, Nguyen T, Berg T, Dalekos GN, Trepo C, Roberts SK, Prieto M, Sorbel J, Anderson J, Mondou E, Rousseau F
The Antiviral Response to Tenofovir Disoproxil Fumarate (TDF) Is Comparable in Lamivudine (LAM)-Naive and LAM-Experienced Subjects treated for chronic Hepatitis B (CHB). Gastroenterology. 2008; 134:A809.
The Antiviral Response to Tenofovir Disoproxil Fumarate (TDF) Is Comparable in Lamivudine (LAM)-Naive and LAM-Experienced Subjects treated for chronic Hepatitis B (CHB)
Primary Care Medicine, 3rd Edition Noble J, Ed.
Primary Care Medicine, 3rd Edition. Primary Care Medicine, 3rd Edition Noble J, Ed. 2001; 900-1026.
Karasik M, Dunzendorfer T, Lee V, Chipkin S, Afdhal NH
Acute hyperglycemia impairs gallbladder motility in normal but not diabetic men. American Journal of Gastroenterology. 1995; (90):1606.
Acute hyperglycemia impairs gallbladder motility in normal but not diabetic men
Bruce R. Bacon, John G. McHutchison, Stuart C. Gordon, Nezam H. Afdhal, Ira M. Jacobson, Mitchell Schiffman, Andrew Muir, Arthur M. Krieg, Susan Elfer, Mary Lou Morris, John Whisnant, Mohammed Al-Adhami, Heather Davis, Tess Schmalbach
Safety, Pharmacodynamic (PD) and Pharmacokinetic (PK) profiles of CPG 10101 (Actilon-TM), a novel TLR9 Agonist: Comparison in Normal Volenteers and HCV infected Individuals. Gastroenterology. 2005; 128(4):p-91.
Safety, Pharmacodynamic (PD) and Pharmacokinetic (PK) profiles of CPG 10101 (Actilon-TM), a novel TLR9 Agonist: Comparison in Normal Volenteers and HCV infected Individuals
Duffy MJ, O'Sullivan F, O'Donoghue D, Afdhal NH, Kelleher D
Ca-19-9, a new marker for gastrointestinal malignancy. Ir J Med Sci. 1985 Oct; 154(10):385-6.
Ca-19-9, a new marker for gastrointestinal malignancy.
Obstructive sleep apnoea syndrome presenting as cardiac arrhythmia. Ir J Med Sci. 1985 Mar; 154(3):120-3.
Obstructive sleep apnoea syndrome presenting as cardiac arrhythmia.
Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):309-10.
Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C.
Ira Jacobson, Robert S Brown, Jr., Nezam Afdhal, Raymond Rubin, James Spivey, Bradley Freilich, Frederick Regenstein, David Bernstein, Robert Doig, Clifford Brass
Clinical Correlates of HCV Genotype and Viral Load: Findings from the WIN-R Trial. Hepatology. 2002; 36(4):376A.
Clinical Correlates of HCV Genotype and Viral Load: Findings from the WIN-R Trial
Maintenance Therapies for Hepatitis C. Current Hepatitis Reports. 2004; 3:23-9.
Hari S. Conjeevaram, University of Michigan, Ann Arbor, MI; Michael W. Fried, University of North Carolina, Chapel Hill, NC; Lennox J. Jeffers, VA Medical Center, Miami, FL; Norah Terrault, UCSF, San Francisco, CA; Thelma E. Wiley-Lucas, Rush University Medical Center, Chicago, IL; Nezam Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Robert S. Brown Jr, New York Presbyterian-Columbia Presbyterian Center, New York, NY; Steve H. Belle, University of Pittsberg, Pittsburgh, PA; Patricia R. Robuck, NIDDK, NIH, Bethesda, MD; Charles D. Howell, University of Maryland, Baltimore, MD
Peginterferon Alfa-2A and ribavirin in African american and caucasian patients with chronic hepatitis C, Genotype 1. hepatology. 2005; 42(4):90A.
Peginterferon Alfa-2A and ribavirin in African american and caucasian patients with chronic hepatitis C, Genotype 1
Feasibility of high-volume screening sigmoidoscopy using a flexible fiberoptic endoscope and a disposable sheath system. Am J Gastroenterol. 1996 Jul; 91(7):1331-7.
Feasibility of high-volume screening sigmoidoscopy using a flexible fiberoptic endoscope and a disposable sheath system.
Qu KZ, Zhang K, Ma W, Li H, Wang X, Zhang X, Giles F, Lai M, Afdhal NH, Albitar M
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease. J Gastroenterol Hepatol. 2011 Apr; 26(4):751-8.
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease.
Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol. 2012 Mar; 56(3):549-56.
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Internal Medicine Heffner JE, Sahn SA, Eds.
A 44 year old woman with sonographic evidence of gallstones. Internal Medicine Heffner JE, Sahn SA, Eds. 2000; 69-71.
A 44 year old woman with sonographic evidence of gallstones
Karasik MS, Dunzendorfer T, Lee V, Chipkin S, Afdhal NH
Acute hyperglycemia impairs gallbladder and small intestinal motility in normal men. Gastroenterology. 1993; (104):530.
Acute hyperglycemia impairs gallbladder and small intestinal motility in normal men
Assessment of liver fibrosis in co-infected patients. J Hepatol. 2006; 44(1 Suppl):S126-31.
Assessment of liver fibrosis in co-infected patients.
Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology. 2006 Jun; 130(7):2229-34.
Iron, HCV, and liver cancer: hard metal setting the pace?
Li S, Vriend LE, Nasser IA, Popov Y, Afdhal NH, Koziel MJ, Schuppan D, Exley MA, Alatrakchi N
Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. Hepatology. 2012 Dec; 56(6):2094-105.
Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.
Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 2013 Mar; 57(3):974-84.
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Nezham Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; Bradley Freilich, Kansas Digetsive Diseases, Kanas City, MO; Robert Levine, Syracuse Univeristy, Syracuse, NY; Maritin Black, Temple University, Philadelphia, PA; Robert Brown Jr, Columbia College of Physicians and Surgeons, New York, NY; Howard Monsour, GI and Liver Associates, Granbury, TX; Michael O'Brien, Boston Medical Center, Boston, MA; Clifford Brass, Schering Plough, Kenilworth, NJ
Colchicine versus PEG- Intron long term (CoPilot) trial: Interim analysis of clinical outcomes at year 2. Hepatology. 2004; 40(4):239A.
Colchicine versus PEG- Intron long term (CoPilot) trial: Interim analysis of clinical outcomes at year 2
Ira M. Jacobson, Weill Medical College of Cornell University, new York, NY; Robert S. Brown, Columbia University College of Physicians & Surgeons, New York, NY; Bradley Freilich, Baptist Medical Center, Kansas City, MO; Nezam Afdhal, beth Israel Deaconess Medical Center, Boston, MA; Pauk Kwo, Indian University School of Medicine, Indianapolis, IN; John Santoro, Atlantic Gastroenterology Associates, Egg Harbor Township, NJ; Scott becker, Austin Gastroenterology, PA, Austin, TX; Adil Wakil, California Pacific Medical Center, San Francisco, CA; David Pound, Indianapolis Gastroenterology Rsch, Indianapolis, IN; Eliot Godofsky, Bach and Godofsky, MD PA, Bradenton, FL; Robert Strauss, Northwest Georgia Gastroenterology Associates, P.C. Marietta, GA; David Bernstein, North Shore University Hospital, Mahasset, NY; Steven Flamm, Northwestern Memorial Hospital, Chicago, IL; Natrajan Bala, Gastroenterology consultants, Houston, TX; Victor Araya, Albert Einstein Medical Center, Philadelphia, PA; Mitchell Davis, SOuth Florida center of Gastroenterology, P.A., Wellington, FL; Howard Monsour, Liver Specialists of Texas, Houston, TX; John Vierling, Cedars-Sinai Medical Center, Los Angeles, CA; Fredric Regenstein, Tulane University Medical School, New Orleans, LA; Vijay Balan, Mayo Clinic, Phoenix, AZ; Michael Dragutsky, GI Consultants of the Midshouth, Memphis; TN; Michael Epstein, Digestive Disorders Associates Annapolis, MD; Robert W. Herring, Nashville, TN; Raymond Rubin, Atlanta Gastroenterology Assoc, Atlanta, GA; Greg Galler, Kelsey-Seubold Clinic, Houston, TX; Mary Pat Pauly, Kaiser Permanente, Sacramento, CA; Louis H. Griffel; Clifford A. Brass, Schering-Plough Research Institute, kenilworth, NJ; the WIN-R S. Group, kenilworth, NJ
Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, A US community based trial. Hepatology. 2005; 42(4):77A.
Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, A US community based trial
Nezam h Afdhal, Betty Goon, Kevin Smith, Zobair Younossi
Epoetin Alfa (EPO) Improves and Maintains Health-Related Quality of Life (HRQL) in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV): HRQL Results from the Proactive Study. Hepatology. 2003; 38(4):302-3A.
Epoetin Alfa (EPO) Improves and Maintains Health-Related Quality of Life (HRQL) in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV): HRQL Results from the Proactive Study
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 09; 381(9865):468-75.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
S.C. Gordon, B.R. Bacon, I.M. Jacobson, M.L. Shiffman, N.H. Afdhal, J.G. McHutchison, T.J. Kwoh, F.A. Dorr
A Phase II, 12-Week Study of ISIS 14083, An Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C. Hepatology. 2002; 36(4):362A.
A Phase II, 12-Week Study of ISIS 14083, An Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C
Inducible nitric oxide is the principal isoform expressed in human gallbladder. Gastroenterology. 1998; (114):526A.
Inducible nitric oxide is the principal isoform expressed in human gallbladder
Afdhal NH, Brand M, Apstein A, Cooley J, Hoffman J, Mikolich D, Grace N, O'Connor C, Nunes DP
Randomized controlled trial of interferon A 5mU daily plus ribavirin 1000mg daily versus interferon A 3mU tiw plus ribavirin 1000mg daily in patients with HCV who have never received previous therapy. Hepatology. 2000; (32):363A.
Randomized controlled trial of interferon A 5mU daily plus ribavirin 1000mg daily versus interferon A 3mU tiw plus ribavirin 1000mg daily in patients with HCV who have never received previous therapy
What prevents digestion of the gallbladder? Phospholipid protects against the toxic effect of taurochenodeoxycholate but not taurocholate. Gastroenterology. 1997; (112):1337A.
What prevents digestion of the gallbladder? Phospholipid protects against the toxic effect of taurochenodeoxycholate but not taurocholate
Cholesterol Gallstone Disease: From Pathogenesis to Prevention. Current Opinion in Gastroenterology. 1994; 10:523-5.
Cholesterol Gallstone Disease: From Pathogenesis to Prevention
Keyur Patel, David R. Nelson, Nezam Afdhal, Esther Oh, Katie Smith, John G. McHutchison, Don Rockey
Prospective Evaluation of a Serum (FibroSpect II) Panel to Predict Fibrosis in Chronic HCV Patients. Gastroenterology. 2004; 126(4):A-708-9.
Prospective Evaluation of a Serum (FibroSpect II) Panel to Predict Fibrosis in Chronic HCV Patients
Afdhal NH, Piggott C, Long AA, O'Donoghue DP
Carbohydrate handling by colonic flora--is it pathogenic in the irritable bowel syndrome? Ir J Med Sci. 1986 Jun; 155(6):197-201.
Carbohydrate handling by colonic flora--is it pathogenic in the irritable bowel syndrome?
O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, Nunes DP
An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol. 2000 Nov; 114(5):712-8.
An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C.
John B Gross, Terry M Therneau, Stephanie M Johnson, Paul Y Kwo, Nezam H Afdhal, Steven L Flamm, RENEW Trial Investigators
The RENEW Trial: A National, Multicenter Study of High-Dose Peginterferon Alfa-2B + Ribavirin for Non-Responders with Hepatitis C. Hepatology. 2003; 38(4):312-13A.
The RENEW Trial: A National, Multicenter Study of High-Dose Peginterferon Alfa-2B + Ribavirin for Non-Responders with Hepatitis C
M. Curry, A. Cardenas, N.H. Afdhal. Liver Center, Beth Israel Deaconess Medical Center, Boston, MA, USA
Effect of Maintenance PEG-Intron Therapy on Portal Hypertension and its Complications: Results from the CoPilot Study. Journal of Hepatology. 2005; 42(4):40.
Effect of Maintenance PEG-Intron Therapy on Portal Hypertension and its Complications: Results from the CoPilot Study
Noah T. Zinkin, Hassan H. Otu, Dimitrios Spentzos, Manuel Aivado, meghan Wells, Towia A. Liberman, Nezam H. Afdhal
proteomic Profiling of Hepatocellular carcinoma with Seldi-Tof Mass Spectrometry in Patients with Chronic Liver Disease. Gastroenterology. 2005; 128(4):a-30.
proteomic Profiling of Hepatocellular carcinoma with Seldi-Tof Mass Spectrometry in Patients with Chronic Liver Disease
Diseases of the Gallbladder and Biliary Tract Afdhal NH, Ed.
Epidemiology and Pathogenesis of Cholesterol Gallstones. Diseases of the Gallbladder and Biliary Tract Afdhal NH, Ed. 2000; 127-46.
Epidemiology and Pathogenesis of Cholesterol Gallstones
Salomons H, Keaveny AP, Henihan R, Offner G, Sengupta A, Lamorte WW, Afdhal NH
Nitric oxide and gallbladder motility in prairie dogs. Am J Physiol. 1997 Apr; 272(4 Pt 1):G770-8.
Nitric oxide and gallbladder motility in prairie dogs.